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ABSTRACT
The Interactions of Cisplatin and Model Proteins Studied by
Electrospray Ionization Mass Spectrometry
and Tandem Mass Spectrometry
Ting Zhao

Protein-cisplatin interactions lie at the heart of both the effectiveness of cisplatin as
an anticancer drug and side effects associated with cisplatin treatment. A greater
understanding of the protein-cisplatin interactions at the molecular level can not only
improve our understanding of the action of cisplatin as an anticancer drug but also inform
the design of cisplatin-like agents for future use. Therefore, the interactions of cisplatin
with three different model proteins were studied, which may provide theoretical basis for
predicating mechanistically relevant protein-cisplatin interactions in biological fluids.
Cytochrome c (cyt c) was used as a model protein to develop a mass spectrometric
approach to determine the primary binding site of cisplatin on proteins by coupling
Fourier transform mass spectrometry (FT-MS) and tandem mass spectrometry (MS/MS
and MS3). FT-MS permits identification of unique fragments in the adduct digest,
characterized by MS/MS and MS3 to indicate that Met65 is the primary binding site for
cisplatin on cyt c.
The interactions of cisplatin and transplatin with myoglobin (Mb) were compared in

order to gain insights into similarities and differences between cisplatin and transplatin in
their interactions with globular proteins. Prior to this research, the conditions for Mb
denaturation were optimized to obtain the Mb digests for MS/MS and MS3.
Cisplatin and transplatin exhibit similar interactions with Mb. Monoadducts and
diadducts were the primary adducts observed in both the interactions. MS/MS and MS3
analyses of the observed unique fragments in the digests of both the Mb-cisplatin and
Mb-transplatin adducts indicate a common binding site for cisplatin and transplatin on the
His116-His119 residues of Mb. This result coupled with a study of the interactions of
cisplatin and transplatin with a dipeptide His~Ser and the three dimensional (3-D)
structure of native Mb shows that cisplatin and transplatin coordinate to the His116 and
His119 residues on Mb.
The binding sites of cisplatin on native ubiquitin (Ub) and denatured Ub were
compared in order to investigate the effect of protein conformation on the cisplatin
binding sites on a protein. Results suggest that cisplatin has more binding sites on the
native Ub than on the denatured Ub due to conformation effect. Three cisplatin binding
sites are determined on the native Ub, in which two threonines are the primary binding
site of cisplatin. On the denatured Ub, the Met1 residue is the specific binding site of
cisplatin.

To My Parents and My Husband
With Love

iv

Acknowledgements

I would like to thank God for blessing me to complete my Ph.D. studies.
I am indebted to my advisor Dr. Fred L. King. His guidance has not only led me to
completing my PhD studies, but also equipped me with skills and abilities to pursue a
chemistry career as an independent researcher.
I am grateful to my committee members Dr. Ronald Smart, Dr. Kenneth Showalter,
Dr. Patrick S. Callery, and Dr. Xiaodong Shi for taking time to be involved in my
graduate studies. They have challenged me to learn and think in a logical way. I will
always be thankful for all their help over these years.
I also want to express my gratitude to all the other faculties, staff, and students at
WVU who have taught me and helped me during my Ph.D. studies. Special thanks to Dr.
Aaron Timperman, Dr. Harry Finklea, and Dr. Lisa Holland. I am grateful to their help
and their knowledge passed on me through classes and my research. I also want to
express my gratitude to Brent Robert Reschke, Kathleen Kelly, Ruijuan Luo, and Dr.
Yuchen Lu for their assistance in my research.
I would like to thank the entire members of the King Group for their friendship and
assistance throughout these years. My Ph.D. studies would have been more difficult
without their friendship and assistance. Special thanks to Megan DeJesus and Dr. Jennifer
Robertson for their time and efforts to help me with my writing.

v

I wish to acknowledge financial support from the Eberly College of Arts and
Sciences at WVU and C. Eugene Bennett Chemistry Department at WVU. Thermo
Finnigan’s gift of the LCQ-MS to WVU was essential to my work. I appreciate the
funding from the NSF EPSCoR program for purchasing the LTQ-FT mass spectrometer. I
wish to thank Dr. Zhongqi Zhang for kindly providing the MagTran software used in my
research.
Finally, I would like to express my appreciation to the support from my family. My
parents and my siblings give me endless love and encouragement over my life. My
husband, Bo Wen, has given me boundless love, constant help, and encouragement
throughout my chemistry career. Without their love and encouragement, I would not be
where I am today.

vi

Table of Contents
Chapter 1.

Introduction ........................................................................................................................ 1

1.1. Cisplatin ................................................................................................................................... 1
1.2. Amino acids, peptides and proteins.......................................................................................... 3
1.2.1. Protein structures........................................................................................................... 4
1.2.2. Cytochrome c (cyt c) ..................................................................................................... 5
1.2.3. Myoglobin (Mb)............................................................................................................ 8
1.2.4. Ubiquitin (Ub)............................................................................................................... 9
1.3. Mass spectrometry ................................................................................................................. 11
1.3.1. Electrospary ionization (ESI) ...................................................................................... 11
1.3.2. Quadrupole ion trap (QIT) .......................................................................................... 14
1.3.3. Tandem mass spectrometry (MS/MS) and multiple stages of mass spectrometry (MSn)
in an ion trap ......................................................................................................................... 17
1.3.4. Linear trap quadrupole (LTQ) ..................................................................................... 19
1.3.5. Identification of covalent modification sites of a protein or peptide by MS/MS and
MSn analyses ......................................................................................................................... 20
1.3.6. Fourier transform mass spectrometry (FT-MS)........................................................... 22
1.4. References.............................................................................................................................. 26
Chapter 2. Direct Determination of the Primary Binding Site of Cisplatin on Cytochrome c by Mass
Spectrometry ......................................................................................................................................... 28
2.1. Introduction ............................................................................................................................ 28
2.2. Experimental .......................................................................................................................... 30
2.2.1. Materials...................................................................................................................... 30
2.2.2. Preparation of the cyt c–cisplatin adducts ................................................................... 31
2.2.3. Protein digestion.......................................................................................................... 32
2.2.4. ESI-MS analyses of the cyt c adducts ......................................................................... 32
2.2.5. FT-MS, MS/MS and MS3 analyses.............................................................................. 33
2.3. Results and Discussion........................................................................................................... 34
2.3.1. Preparation of the cyt c-cisplatin adducts.................................................................... 34
2.3.2. Determination of the primary binding site of cisplatin on cyt c.................................. 37
2.3.2.1 Protein digestion........................................................................................................ 37
2.3.2.2. Determination of the primary binding site from Fragment #1 and Fragment #2 ..... 41
2.3.2.3. Identification of Fragment #3 and Fragment #4....................................................... 46
2.4. Conclusions............................................................................................................................ 49

vii

2.5. References.............................................................................................................................. 50
Chapter 3. Myoglobin Denaturation ..................................................................................................... 51
3.1. Introduction ............................................................................................................................ 51
3.2. Experimental .......................................................................................................................... 52
3.3. Results and Discussion........................................................................................................... 53
3.3.1. Tryptic digestion of free Mb under native conditions ................................................. 53
3.3.2. Thermal denaturation .................................................................................................. 54
3.3.3．Protein denaturation by a mixed methanol-aqueous solvent ..................................... 57
3.4. Conclusions............................................................................................................................ 61
3.5. References.............................................................................................................................. 62
Chapter 4. A Mass Spectrometric

Comparison of the Interactions of Cisplatin and Transplatin with

Myoglobin............................................................................................................................................. 63
4.1. Introduction ............................................................................................................................ 63
4.2. Experimental .......................................................................................................................... 65
4.2.1. Materials...................................................................................................................... 65
4.2.2. The kinetics studies of Mb-cisplatin and Mb-transplatin interactions......................... 66
4.2.3. The digestion of Mb-cisplatin and Mb-transplatin adducts......................................... 67
4.2.4. Reactions of the Mb-cisplatin and Mb-transplatin adducts with 5’-GDP ................... 67
4.2.5. ESI-MS and MSn ......................................................................................................... 68
4.3. Results and Discussion........................................................................................................... 69
4.3.1. The kinetics of the Mb-cisplatin and Mb-transplatin interactions............................... 69
4.3.2. The Mb-cisplatin and Mb-transplatin adducts............................................................. 71
4.3.3. Determination of the cisplatin and transplatin binding sites on Mb............................ 73
4.3.3.1. The digestion of the Mb-cisplatin and Mb-transplatin adducts ................................ 73
4.3.3.2. FT-MS analyses of the digests.................................................................................. 73
4.3.3.3. Identification of the peptide sequence of the 1313.275+ ion..................................... 79
4.3.3.4. Determination of the Pt(NH3) binding site on His97-Gly153 .................................. 84
4.3.3.5. The assignment of the residues coordinated to Pt(NH3) in the HSKH residues....... 88
4.3.4. The stability of the Mb-cisplatin and the Mb-transplatin adducts............................... 90
4.4. Conclusions............................................................................................................................ 92
4.5. References.............................................................................................................................. 93
Chapter 5. A Mass Spectrometric Comparison of the Binding Sites of Cisplatin on Native and
Denatured Ub: Evidence of the Effect of Protein Conformation on Protein Platination....................... 94
5.1. Introduction ............................................................................................................................ 94
5.2. Experimental .......................................................................................................................... 97

viii

5.2.1. Materials...................................................................................................................... 97
5.2.2. Formation of native and denatured Ub-cisplatin adducts............................................ 97
5.2.3. Trypsin digestion of the Ub-cisplatin adducts ............................................................. 98
5.2.4. ESI-MS and FT-MS analyses ...................................................................................... 98
5.3. Results and Discussion........................................................................................................... 99
5.3.1. Formation of the Ub-cisplatin adducts under the native and denatured conditions .... 99
5.3.2. Determination of the cisplatin binding sites on Ub under the native and denatured
conditions ............................................................................................................................ 102
5.3.2.1. Determination of cisplatin binding sites on native Ub ........................................... 106
5.3.2.1.1. The binding site of Pt(NH3)2 on the 876.402+ ion................................................ 106
5.3.2.1.2. The binding sites of Pt(NH3) on the 975.41+ ion................................................. 109
5.3.2.1.3. The Pt(NH3)2 binding sites on the 1008.472+ ion................................................. 110
5.3.2.2. Determination of the cisplatin binding site on denatured Ub................................. 112
5.4. Conclusions.......................................................................................................................... 115
5.5. References............................................................................................................................ 116
Future Directions................................................................................................................................. 117

ix

List of Figures
Figure 1.1. The structures of cisplatin and transplatin ................................................................... 3
Figure 1.2. The structures of (A) an amino acid and (B) a tripeptide............................................. 4
Figure 1.3. The 3-D structure of cyt c and the structure of the heme group................................... 7
Figure 1.4. The Mb structure (A) The 3-D structure of Mb in which the polypeptide is blue and
the heme group is red. (B) The structure of the active site when CO binds to Fe in the heme
group. Adapted from reference 12........................................................................................... 9
Figure 1.5. The 3-D structure of ubiquitin ................................................................................... 10
Figure 1.6. Schematic of the ESI processes, adapted from reference 19...................................... 13
Figure 1.7. Schematic of a quadrupole ion trap............................................................................ 15
Figure 1.8. The types of the product ions generated by MS/MS .................................................. 21
Figure 1.9. Schematic of a FT-MS instrument ............................................................................. 25
Figure 2.1. The cyt c sequence ..................................................................................................... 31
Figure 2.2. The percentage of cyt c-Pt(NH3)2(H2O) in three cyt c-cisplatin solutions: ( ) 1:4 cyt
c:cisplatin; () 1:8 cyt c: cisplatin; (

) 1:12 cyt c:cisplatin at different time intervals over

30 hours................................................................................................................................. 35
Figure 2.3. Deconvoluted ESI-MS spectra of free cyt c and the cyt c-cisplatin adducts obtained
by incubating cyt c and cisplatin at different molar ratios for 24 h under native conditions.
The assignment of individual peaks: A) cyt c; B) cyt c-H2O; C) cyt c-(H2O)2; .................... 36
Figure 2.4. The FT-MS spectrum of the free cyt c digest............................................................. 39
Figure 2.5. The FT-MS spectrum of the adduct digest ................................................................. 39
Figure 2.6. The product-ion spectrum of the MS/MS analysis of the 1507.7774+ ion and zoom
scans of the product ions 1456.272+ and 1558.182+ ............................................................... 42
Figure 2.7. The product-ion spectrum of the MS3 analysis of the 1507.7774+ ion at m/z 1456.27.
The peptide sequence of the 1456.272+ ion : (Met80-Glu104) MIFAGIKKKTEREDLI AYL
KKA .................................................................................................................................... 43
Figure 2.8. The product-ion spectrum of the MS3 analysis of the 1507.7774+ ion at m/z 1558.18.
The peptide sequence of the 1558.182+ ion: (Gly56-Lys79) GITWKEETLMEYLENPKKY
IPGTK................................................................................................................................... 45
Figure 2.9. The product-ion spectrum of the MS/MS analysis of the 1568.3114+ ion and zoom
scan of the product ion 1679.272+ ......................................................................................... 46

x

Figure 2.10. The product-ion spectrum of the MS/MS analysis of the 1275.0375+ ion. The peptide
sequence of the 1275.0375+ ion: (Acetyl-Gly1-Lys53) Acetyl-GDVEKGKKIFVQKCA
QCHTVEKGGKHKTGPNLHGLFGRKTGQAPGFTYTDANK ........................................ 48
Figure 2.11. The product-ion spectrum of the MS/MS analysis of the 1323.4635+ ion. The peptide
sequence of the 1323.4635+ ion: (Acetyl-Gly1-Lys55) Acetyl-GDVEKGKKIFVQKCAQ
CHTVEKGGKHKTGPNLHGLFGRKTGQAPGFTYTDANKNK ..................................... 48
Figure 3.1. The native Mb digest after tryptic digestion for 21 h................................................. 54
Figure 3.2. The free Mb digest obtained by trypsin digestion for 17 h after thermal denaturation
............................................................................................................................................... 56
Figure 3.3. The Mb-cisplatin adduct digest obtained by trypsin digestion for 17 h after thermal
denaturation........................................................................................................................... 56
Figure 3.4. The Mb digest obtained by trypsin digestion after denaturation in a 50%
MeOH-25mM NH4HCO3 solvent ......................................................................................... 59
Figure 3.5. The Mb digest obtained by trypsin digestion after denaturation in a 60%
MeOH-25mM NH4HCO3 solvent ......................................................................................... 59
Figure 3.6. The Mb digest obtained by trypsin digestion after denaturation in a 70%
MeOH-25mM NH4HCO3 solvent ......................................................................................... 60
Figure 3.7. The Mb adduct digest obstained by trypsin digestion after solvent denaturation with a
70% MeOH-25mM NH4HCO3 solvent ................................................................................. 60
Figure 4.1. The structures of cisplatin, transplatin, guanosine 5’-monophosphate, and the Mb
sequence ................................................................................................................................ 66
Figure 4.2. The kinetics plots for the Mb-cisplatin and Mb-transplatin solutions obtained by
monitoring the percentages of the Mb species in the respective solutions as a function of
time:(a) The Mb-cisplatin solution; (b) The Mb-transplatin solution ................................... 71
Figure 4.3. Deconvoluted ESI-QITMS spectra of free Mb and the Mb-cisplatin and
Mb-transplatin adducts obtained by reacting Mb with cisplatin and transplatin for 27 hours
............................................................................................................................................... 72
Figure 4.4. FT-MS spectrum of the free Mb digest ...................................................................... 76
Figure 4.5. FT-MS spectrum of the Mb-cisplatin adduct digest................................................... 76
Figure 4.6. FT-MS spectrum of the Mb-transplatin adduct digest................................................ 76
Figure 4.7. Expanded FT-MS spectrum of the free Mb digest ..................................................... 77
Figure 4.8. Expanded FT-MS spectra of the Mb-cisplatin digest................................................. 77
Figure 4.9. Expanded FT-MS spectra of the Mb-transplatin digest.............................................. 77
Figure 4.10. The product-ion spectrum of the 1313.275+ ion. The peptide sequence of the
1313.275+ ion: (His97-Gly153) HKIPIKYLEFISDAI IHVLHSKHPGDFGADAQGAMTK
ALELFRNDIAAKYKELGFQG .......................................................................................... 78

xi

Figure 4.11. The product-ion spectrum of the 1316.685+ ion. The peptide sequence of the
1316.685+ ion: (His97-Gly153) HKIPIKYLEFISDAIIHVLHSKHPGDFGADAQGAMTK
ALELFRNDIAAKYKELGFQG .......................................................................................... 78
Figure 4.12. The product–ion spectrum of the MS3 analysis of the 1313.275+ ion at the y272+ ion.
The peptide sequence of the y272+ ion: AQGAMTKALELFRNDIAAKYKELGFQG ......... 80
Figure 4.13. The product–ion spectrum of the MS3 analysis of the 1313.275+ ion at the y312+ ion.
The peptide sequence of the y312+ ion: FGADAQGAMTKALELFRNDIAAKYKELGFQG
............................................................................................................................................... 81
Figure 4.14. The product–ion spectrum of the MS3 analysis of the 1313.275+ ion at the y342+ ion.
The peptide sequence of the y342+ ion: PGDFGADAQGA MTKALELFRNDIAAKYKEL
GFQG.................................................................................................................................... 81
Figure 4.15. The isotope distributions of the 1542.004+ and 1570.454+ ions in Figure 4.10. ........ 83
Figure 4.16. The product–ion spectrum of the MS3 analysis of the 1313.275+ ion at m/z 1542.00.
The peptide sequence of the 1542.004+ ion: PIKYLEFISDAIHVLHSKHPGDFGADA
QGAMTKALELFRNDIAA KYKELGFQG ........................................................................ 83
Figure 4.17. The product–ion spectrum of the MS3 analysis of the 1313.275+ ion at m/z 1570.45.
The peptide sequence of the 1570.454+ ion: IPIKYLEFISDAIIHVLHSKHPGDFGAD
AQGAMTKALELFRNDIAAKYKELGFQG ...................................................................... 84
Figure 4.18. The isotope distribution of the 972.153+ ion and the MS3 analysis of the 1313.275+
ion at m/z 972.15. The peptide sequence of the 972.153+ ion: (His97-His119)
HKIPIKYLEFISD AIIHVLHSKH ....................................................................................... 86
Figure 4.19. The isotope distribution of the 1444.453+ ion and the MS3 analysis of the 1313.275+
ion at m/z 1444.45 and. The peptide sequence of the 1444.453+ ion: (His116-Gly153)
HSKHPGDFGADAQGAMTKALELFRNDIAAKYKELGFQG ........................................ 87
Figure 4.20. The Ribbon diagram of the 3-D structures of the Mb polypeptide chain under native
conditions with the side chains of the HSKH residues displayed 12...................................... 89
Figure 4.21. The percentage of each Mb species after reacting the Mb adducts with 5’-GMP for
different hours over 3 days: (a) The reaction of Mb-cisplatin adducts with 5’-GMP; (b) The
reaction of Mb-transplatin adducts with 5’-GMP ................................................................. 91
Figure 5.1. The Ub sequence........................................................................................................ 97
Figure 5.2. The percentages of the formed Ub-cisplatin monoadducts under the native and
denatured conditions in 30 hours ........................................................................................ 100
Figure 5.3. The deconvoluted ESI mass spectra of the Ub monoadducts yielded by the
Ub-cisplatin interactions under native and denatured conditions over 12 h and 24 h,
respectively. Peak assignment: (a) free Ub; (b) Ub-Pt; (c) Ub-Pt(NH3); (d) Ub-Pt(NH3)2; (e)
Ub-Pt(NH3)2(H2O); (f) Ub-Pt(NH3)2(H2O)2; (g) Ub-Pt(NH3)(CH3CO2). ........................... 102

xii

Figure 5.4. The free Ub digest.................................................................................................... 104
Figure 5.5. The digest of the Ub adduct obtained under the native conditions .......................... 104
Figure 5.6. The digest of the Ub adduct obtained under the denatured conditions .................... 104
Figure 5.7. The isotope distributions of three Pt-compound containing fragments, the 876.402+,
975.41+, and 1008.472+ ions, in the native Ub adduct digest. ............................................. 105
Figure 5.8. The isotope distributions of three Pt-compound containing fragments, the 975.41+,
1148.923+, and 1631.832+ ions, in the denatured Ub adduct digest ..................................... 106
Figure 5.9. The product-ion spectrum of the MS/MS analysis of the 876.402+ ion, overlaid with
the isotope distribution of the 977.36+ product ion. The peptide sequence of the 876.402+ ion:
(I30-R42) IQDKEGIPPDQQR ........................................................................................... 108
Figure 5.10. The product-ion spectrum of the MS3 analysis of the 876.402+ion at m/z 977.36. The
peptide sequence of the 977.36+ ion: (I30-I36) IQDKEGI ................................................. 108
Figure 5.11. The product-ion spectrum of the MS/MS analysis of the 975.41+ ion. The peptide
sequence of the 975.41+ ion: (M1-K6) MQIFVK ............................................................... 110
Figure 5.12. The product-ion spectrum of MS/MS analysis of the 1008.472+ ion, overlaid with
the isotope distribution with the product ion 622.18+. The sequence of the 1008.472+ ion:
(T12-K27) TITLEVEPSDTIENVK .................................................................................... 112
Figure 5.13. The product-ion spectrum of the MS/MS analysis of the 1148.923+ ion. The peptide
sequence of the 1148.923+ ion: M1-K29 MQIFVKTLTGKTITLEVEPSDTIENVKAK ... 113
Figure 5.14. The product-ion spectrum of the MS/MS analysis of the 1623.322+ ion. The peptide
sequence of the 1623.322+ ion: M1-K27 MQIFVKTLTGKTITLEVEPSDTIENVK ......... 114

xiii

List of Table
Table 2.1. Four new fragments in the FT-MS spectrum of the adduct digest identified by MS/MS
and MS3 analyses ................................................................................................................. 40

xiv

Chapter 1.

Introduction

1.1. Cisplatin
Cisplatin, cis-diamminedichloroplatinum, is an effective anticancer drug,
particularly for testicular and ovarian cancers. It was first synthesized by Michel
Peyrone in 1845. But its anti-tumor activity was not discovered until the early 1960s 1,
when Barnett Rosenberg studied how an electric field affects bacterial cell growth
using a platinum electrode. He found that the cell division stopped but continued to
grow. It was concluded that cell division ceased due to the formation of cisplatin
produced by the reaction between the Pt electrode and the bacterial solution.

This

discovery led to the consideration of cisplatin as an anticancer agent. The anticancer
activity of cisplatin was tested against mice tumors, from which it was discovered that
cisplatin was highly effective in cancer treatment. Cisplatin’s use in chemotherapy
began in the 1970s 2.

It is believed that the anticancer activity of cisplatin arises from its binding to
DNA, thereby interrupting DNA replication and stopping cell division. Intact cisplatin
enters the tumor cells mainly by diffusion through the membrane 3. Studies also
indicated that copper-transporting proteins can transport cisplatin into tumor cells 4.

1

Because there is a low chloride concentration inside the tumor cells, the highly
reactive complex Pt(NH3)2Cl(H2O)+ is produced by displacing one chloride with one
water. The highly reactive Pt(NH3)2Cl(H2O)+ species usually binds to the N7 atom on
guanine (G) base in DNA. After the remaining chloride is substituted by water, the N7
atom on the adjacent guanine displaces the water and binds to Pt, resulting in the
formation of an intrastrand-crosslink DNA-Pt(NH3)2 adduct. Then, a high mobility
group (HMG)-domain protein recognizes the DNA-Pt(NH3)2 complex and binds to it.
The formation of DNA-Pt(NH3)2-HMG adducts cause distortion of the double
stranded DNA helix, which stops DNA replication and induces cell apoptosis.

Before reaching DNA, cisplatin interacts with proteins, particularly sulfur
containing proteins, in blood plasma due to a high affinity between cisplatin and
sulfur-containing species. One day after injection, 65%-98% of cisplatin was reported
to be associated with blood plasma proteins 5. Because cisplatin has a high affinity for
sulfur-containing proteins, some cisplatin ends up accumulating in non-malignant
cells. Such irreversible protein-cisplatin interactions are blamed for side effects of
cisplatin. However, studies indicate that the blood plasma proteins might be
responsible for transporting cisplatin to its DNA target 6. The exact role that the
cisplatin-blood plasma protein adducts play in cisplatin action remains ambiguous.

Transplatin (trans-diamminedichloroplatinum)

7

is the geometric isomer of

cisplatin. But transplatin has no anticancer activity because the binding of transplatin
to DNA cannot form an intrastrand crosslink. Therefore, the HMG-domain protein

2

cannot bind to transplatin-modified DNA to stop cell devision.

Cisplatin

Transplatin

Figure 1.1. The structures of cisplatin and transplatin

1.2. Amino acids, peptides and proteins
There are 20 amino acids, the general structures of which are shown in Figure
1.2. All of the amino acids have three common components: a primary amino group, a
carboxylic acid, and a central carbon with an attached hydrogen atom. The difference
in the structures of the amino acids lies only in the structure of their side chains (R).
Therefore, the properties of amino acids are determined by their side chains 8.

Proteins and peptides are linear polymers of the amino acid residues, connected
by peptide bonds formed by condensation reactions between the amino group of one
amino acid and the carboxylic group of the adjacent amino acid. Peptides consist of
two or more amino acid residues, and proteins consist of one or more peptides with a
total number of amino acid residues ranging from 40 to 4000. Figure 1.2. shows the

3

structure of a tripeptide. The amino acid residues in the middle of the peptide chain
are linked to neighbors by two peptide bonds. Two amino acids at the two terminals
form only one peptide bond. The terminal residue with the free amino group is called
the N terminus of the peptide and the terminal residue with the free carboxylic acid is
called the C terminus of the peptide. The direction of polypeptide chains is defined
from the N terminus to the C terminus.

(A)

(B) N terminus

R
NH2

+

NH3

CH

CO2H

R1

O

CH

C

NH

R2

O

CH

C

R3
NH

CH

C O2- C terminus

Figure 1.2. The structures of (A) an amino acid and (B) a tripeptide

1.2.1. Protein structures
Proteins carry out various functions in biological processes, such as catalyzing
biochemical reactions, transporting and storing biologically important molecules,
serving as messengers in signal transduction, and so on. The function of a protein is
dictated by its structure, described by a four-level hierarchy 9:
A protein’s primary structure is the amino acid sequence from the N terminus to
the C terminus. The primary structure of each protein dictates its higher order protein
structure.
A protein’s secondary structure describes the spatial arrangement of the atoms on
the polypeptide backbones. Hydrogen bonds are formed between NH and C=O on the
4

protein backbone in order to stabilize the structure of the protein. α-Helices and βsheets are the most common spatial backbone arrangement caused by the formation of
the hydrogen bond. On the same peptide chain, the hydrogen bonds are formed by
interactions of the C=O group on the nth amino acid residue with the N-H group on
the (n+4)th amino acid residue. Such hydrogen bonds drive the entire backbone to
fold into an α-helix. β-Sheets are formed due to the hydrogen bonding of N-H and
C=O groups on the backbone of adjacent polypeptide chains. Comparing the direction
of polypeptide chains, β-sheets are divided into anti-parallel β-sheets and parallel
β-sheets.
The tertiary structure of a protein describes the folding of the entire polypeptide
chain including the side chains, driven by hydrophobic force. Non-polar side chains
are folded inside the hydrophobic core and the polar residues are exposed to the
protein surface. In biological systems, water-soluble proteins are folded in such a way
that the hydrophobic side chains are buried inside the protein and the hydrophilic side
chains are exposed at the surface.
The quaternary structure is the arrangement of two or more polypeptides in a
protein. The quaternary structure is stabilized by noncovalent interactions between
polypeptide chains.

1.2.2. Cytochrome c (cyt c)
Cyt c is a small hemoprotein attached to a mitochondrial membrane. It serves as
an electron transfer protein by transporting electrons from one complex to another
complex embedded inside the membrane. During electron transfer, cyt c is either

5

oxidized or reduced. Therefore, cyt c plays an important role in the processes that
involve energy production and electron transfer reactions in cells such as
mitochondrial respiration.

Horse heart cyt c is a well-characterized protein due to its small size (M.W.
12386 Da) and high solubility in water. The heme is the prosthetic group of cyt c,
consisting of an iron atom and a porphyrin, a highly conjugated organic molecule
coordinated to the iron atom. During electron transfer, cyt c is oxidized by converting
Fe (II) to Fe (III), and vice versa in the reduction of cyt c.

The three dimensional (3-D) structure of horse heart cyt c and the structure of
the heme are shown in Figure 1.3.

10

. The heme is covalently linked to cyt c by

formation of two thioether bonds between two vinyl groups on porphyrin and the side
chains of two cysteine residues (Cys14 and Cys17) on cyt c. The formed thioether
covalent bonds stabilize the heme group at the protein surface for electron transfer.
The central iron atom in the heme group coordinates to six ligands, among which four
are the nitrogen atoms on the porphyrin ring and two are amino acid residues from cyt
c at the axial position including one immidazole nitrogen of His18 and one sulfur
atom of Met80.
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Figure 1.3. The 3-D structure of cyt c and the structure of the heme group 10 11
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1.2.3. Myoglobin (Mb)
Mb is ared hemoprotein in muscle cells and serves as an O2 reservoir by
reversibly binding to O2 and facilitating O2 transportation to mitochondria under
anoxic conditions 12,13. It is a small globular protein and contains a single polypeptide
of 153 amino acids and a heme group as the prosthetic group. The Mb backbone is
folded into 8 α-helices labeled A-H and several short loops. The entire polypeptide
chain is further folded into a tight globular structure, leaving a pocket at helix C, E
and F for the heme group. The heme group is located between His64 and His93 and
held in the pocket by the covalent interaction between His93 and Fe.

In deoxymyoglobin, the iron atom in the heme group only coordinates to 5
ligands, 4 nitrogen atoms on the porphyrin, and 1 nitrogen atom from imidazole of
His93 in the axial position. The coordination to His93 pulls the iron atom slightly out
of the the porphyrin plane. The other coordination site at the axial position is the
potential binding site for O2, CO, or NO. When CO (O2 or NO) binds Fe, it pulls Fe
back into the porphyrin plane and forms a hydrogen bond with distal His64, shown in
Figure 1.4. The change of the Fe position relative to the porphyrin plane suggests the
binding of O2 involves a conformational change of Mb.
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Figure 1.4. The Mb structure (A) The 3-D structure of Mb in which the polypeptide is blue and
the heme group is red. (B) The structure of the active site when CO binds to Fe in the heme
group. Adapted from reference 12.

1.2.4. Ubiquitin (Ub)
Ub

14,15

is a small protein with a molecular weight of 8565 Da. It is ubiquitous in

eukaryotic cells and can be isolated from a variety of sources. The sequences of
ubiquitins from different sources are highly indistinguishable. Humans, bovines, and
insects have identical sequences from the first amino acid at the N terminus to the
74th amino acid residue. Ub carries out many functions within the cell by covalently
interacting with target proteins. For example, ubiqutin performs an important role in
regulating protein degradation. Ub can recognize old proteins, selectively bind to
them, and form protein-ubiquitin complexes through covalent interactions between
the carboxylic group at the C terminus of ubiquitin and the amino group of the lysine
residue in the target protein. The formation of these complexes indicates that the cell
9

is ready to degrade.

Ub is a small protein of a single polypeptide with 76 amino acids. The
polypeptide backbone is folded into 2 α-helices and 5 β-strands, and a few turns and
coils, which are shown in Figure 1.5. The entire polypeptide chain is tightly folded by
hydrogen bonding. Ub is very stable and resistant to proteolysis under extreme
conditions.

Figure 1.5. The 3-D structure of ubiquitin 16
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1.3. Mass spectrometry
A mass spectrometer primarily includes three parts: an ionization source to
produce ions in the gas phase, a mass analyzer to separate the ions by their mass to
charge ratio (m/z), and a detector to measure the abundance of the separated ions. The
features of a mass spectrometer are always described by its ionization source and
mass analyzer. In this dissertation, electrospray ionization is used as the ionization
source to ionize proteins, peptides, and protein-Pt metallodrug adducts. The resultant
ions undergo mass analysis in either quadrupole ion trap or Fourier transform mass
spectrometry systems.

1.3.1. Electrospary ionization (ESI)
ESI is an ionization technique used to transfer ions directly from aqueous
solution into the gas phase. Since its introduction by Yamashita and Fenn in 1984 17,18,
it has become the most important technique in biological mass spectrometry because
of its ability to ionize thermally labile molecules. A high voltage (2-5 kV) is applied to
a metal capillary, which is placed 1-3 cm away from the grounded ion sampling
orifice of a mass spectrometer. Because the tip of the metal capillary is very thin, an
extremely strong electric field is created at the capillary tip when the high voltage is
applied. This electric field (Ec) can be estimated by Equation (1)
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Ec =

2Vc
rc ln(4d / rc )

Equation (1)

Where Vc is the applied voltage, rc is the radius of the metal capillary, and d is
the distance of the tip to the orifice of the mass spectrometer. If a voltage of 4 kV is
applied to a metal capillary (rc =10-4 m) and there is a distance of 0.03 m from the
capillary tip to the counter electrode, an electric field of 107 volts/m is generated
according to Equation 1.

Either positive or negative voltages can be applied to the capillary; the polarity is
determined by the nature of the analyte. Because proteins and peptides are analyzed
under the positive mode in this dissertation, the positive mode is used to describe the
mechanism of ESI for this work 19.

Figure 1.6. shows the schematic of the ESI process. An analyte solution is
pumped through a silica capillary, which is in contact with the metal capillary, at a
flow rate of (0.1-10 uL/min). When the positive voltage (2-5 kV) is applied to the
metal capillary, the electric field will penetrate into the solution. Under the influence
of the electric field, positively charged ions in the solution will drift down the field
and toward the meniscus of the solution at the capillary tip. Negatively charged ions
will drift away from the capillary tip. Because of the accumulation of the positive ions
at the capillary tip, the coulombic repulsion between the positively charged ions will
force the liquid surface of the meniscus to expand and form a “Taylor cone” 20. If the
electric field is high enough, the surface tension is overcome and a fine jet with small

12

charged droplets will emerge as the cone breaks down. In commercial instruments,
droplet formation is assisted by using a sheath gas around the capillary tip. The sheath
gas also aids in solvent evaporation and droplet shrinkage. As the droplets shrink by
evaporation, the coulombic repulsion overcomes the surface tension, leading to the
droplets’ fission into smaller droplets. This repeated evaporation and fission process
produces very small charged droplets (<10 nm in diameter). The origin of gas phase
ions from the small droplets is still in debate. Two mechanisms, ion evaporation
mechanism (IEM) and charged residue mechanism (CRM), are used to describe the
process.

Figure 1.6. Schematic of the ESI processes, adapted from reference 19

IEM was formulated by Iribarne and Thomson

13

21,22

based on transition state

theory. In a droplet, the coulombic repulsion of the other ions to the escaping ion and
the attraction of the polar solvent to the escaping ion are opposed to each other at the
transition state. Once the coulombic repulsion can overcome the attraction, the ions
can be directly emitted from very small droplets with radii less than 10 nm. Dole and
his coworkers

23

proposed CRM, which states that the gas phase ion is yielded by

continuous droplet shrinkage and fission due to coulombic repulsion. These two
mechanisms are useful to explain some results but the mechanism of ESI of is still
under investigation.

1.3.2. Quadrupole ion trap (QIT)
The quadrupole ion trap (QIT) was introduced by Paul and Steinwedel in 1960 24,
but it did not find widespread use until the 1980s. QIT is considered the workhorse of
biochemical research because of its mechanical and operational simplicity, simple
vacuum requirement, ruggedness, high sensitivity, and compatibility with different
ionization sources 25.
A schematic representation of QIT is displayed in Figure 1.7. As shown in Figure
1.7, the QIT consists of two hyperbolic endcaps and one donut-shaped ring electrode.
r is the radial direction of the QIT and is defined as the distance from the center of the
ion trap to the closest point on the ring electrode. z represents the axial direction and
is the distance from the center of the QIT to the endcaps. Both endcaps have one hole
in the center. One is for ion injection and the other is for ion ejection 26.
14

Figure 1.7. Schematic of a quadrupole ion trap

In the application of a QIT as a mass analyzer, a fundamental RF with a fixed
frequency is applied to the ring electrode and an electric field that traps the ions is
generated. The strength of the electric field is linearly related to the distance to the
center of the QIT, i.e. the center has the weakest electric field but the electric field
increases in strength toward the edges of the QIT. For this reason, ions at the center
experience a weak electric field, but ions at the edges experience a much stronger
force which drives the ions toward the center.
The motion of an ion in the QIT is described by the Mathieu equation. From the
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Mathieu equation, two parameters (au and qu) are obtained and used to describe the
stability of the ion in both z and r directions. Because only an RF potential is applied
to the ring electrode in commercial instruments, the stability of the ion is described by
qz, which is shown in Equation 2 26. Ions with qz < 0.908 can be trapped.
q z = −2 q r =

8eV
m ( r + 2 z 2 )Ω 2
2

Equation (2)

In equation 2, m is the mass of the ion; e is the charge of the ion; r and z refer to
the distance from the center to the ring electrode and to the endcaps along the radial
and axial direction, respectively; Ω and V are the frequency and the amplitude of the
fundamental RF voltage. In reality, r, z, and Ω are fixed. The stability of the ion is
determined by V and m/z of the ions. the mass range of the trapped ions is determined
by the RF amplitude in Equation 2.
During ion injection, the high kinetic energy of the injected ions leads to ion
spread and even direct ejection of the ions. 1 mTorr He is used in the QIT to dampen
the kinetic energy of the injected ions by collisional cooling 27, thereby improving the
injection efficiency and the resolution of the QIT. Meanwhile, the number of ions that
can be placed in the trap is limited because of space-charge effects. If the trap is
over-filled, the ions will repel each other, which will spread out the ion cloud and
destroy the resolution of the QIT. On the other hand, insufficient ion loads will result
in weak signals. Ion accumulation for low abundance ions is performed over a longer
time period in the ion trap in order to increase the number of ions in the QIT and
improve detection signals before ion ejection.
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The ions are ejected by mass selective instability 28 and resonance ejection 29 for
mass analysis. In mass selective instability, the ions are sequentially ejected out of the
trap from low to high mass by ramping the RF amplitude. The ions with a large m/z
require a large RF voltage to be destabilized. In reality, there is an upper limit to the
RF amplitude such that only ions <m/z 650 can be ejected, otherwise electric
breakdown occurs in the trap.
Ions >m/z 650 are ejected by resonance ejection. In the QIT, each ion has a
unique secular frequency, which describes the periodicity of its motion inside the trap.
The secular frequency of each ion will change as the RF amplitude changes. If the
secular frequency of an ion is in resonance with the amplitude of the supplementary
RF, the ion will gain kinetic energy and exit the trap. Thus, resonance ejection is
performed by ramping the RF amplitude of the supplementary RF voltage to eject
ions. The employment of resonance ejection significantly increases the mass range of
the QIT.

1.3.3. Tandem mass spectrometry (MS/MS) and multiple stages of
mass spectrometry (MSn) in an ion trap
MS/MS and MSn provide structural information for a parent ion 30. Two stages of
mass analysis are involved in MS/MS in an ion trap. The first stage isolates the parent
ion and the second stage analyzes the product ions after ion activation. In the ion trap,
the ions are often activated by collision induced dissociation (CID) 31, in which ions
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are forced to collide with neutral gas atoms or molecules, frequently the damping gas
He, by applying a supplemental potential to the ion trap. The kinetic energy of the
parent ion is converted into internal energy during CID, leading to ion fragmentation
in the gas phase. If this process is repeated to provide more structural information of
a product ion, it is called MS3. MSn is to repeat ion isolation, ion activation, and mass
analysis for multiple times.

MS/MS and MSn analysis is performed in the ion trap by carrying out each stage
of mass analysis sequentially in time

26

. The parent ions are isolated by the

combination of mass selective instability and resonance ejection. Once isolated within
the ion trap, the parent ion is activated by CID. In CID, a supplementary RF voltage is
applied to the endcaps in order to increase the kinetic energy of the parent ion. The
applied amplitude of the supplementary RF voltage is smaller than that used to eject
the ions out of the trap. Multiple collisions between the accelerated ions with the
target gas (He) lead to dissociation of the parent ion and production of fragment ions.
The obtained fragment ions are ejected by mass selective instability and resonance
ejection for mass analysis. The processes of ion isolation, ion activation, and ion
detection can be repeated for the product ions to obtain more structural information.
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1.3.4. Linear trap quadrupole (LTQ)
In a LTQ, ions is confined in the axial position by applying stopping
potentials at the entrance and the exit of the LTQ

32

. A two dimensional (2-D)

electric field is applied to a square array of quarupole rods to confine the ions in
the radial direction. Because of the application of the 2-D electric field, the ion
motions inside the LTQ are so complex that the motions in the x and y directions
cannot be described separately. Because there is no sharp boundary between
stability and instability, no stability diagram can be used to describe the stability
of ions in the LTQ. The ion trajectories and its oscillation frequency strongly
depend on the initial conditions of each ion.
The basis for ion trapping, collision cooling, ion excitation, and ion
detection in the LTQ is similar to QIT 33. Ions are trapped at low amplitude of the
fundamental RF potential. Helium is used as damping gas to reduce the kinetic
energies of the ions and confine the ions in the center of the LTQ. The
fundamental RF potential applied to the quadrupoles is ramped to eject ions for
ion detection and a supplementary RF potential is applied at the same time to
accelerate the ion ejection. In MS/MS, the ions are forced to collide with the
target gas He by applying a smaller supplementary RF voltage to induce ion
dissociation.
Ion isolation in the LTQ is different from that in QIT. Three voltages
including ion isolation waveform voltage, resonance excitation voltage, and
resonance ejection voltage are applied to the ejection electrodes to eject all
unwanted ions. Because the LTQ has a larger dimension than a QIT, the LTQ
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provides higher ion injection efficiency and storage capacity, and is less affected
by space charge effects than QIT. Moreover, the LTQ is compatible with other
mass analyzers such as FT-MS to form hybrid instruments. Collision cooling of
the ions in the LTQ before entering FT-MS stabilizes the motion of the ions to
provide a more coherent ion packet for injection 34.

1.3.5. Identification of covalent modification sites of a protein or
peptide by MS/MS and MSn analyses
Product-ion spectra obtained from MS/MS analysis of peptides in an ion trap
enable peptide sequencing, protein identification, and protein covalent
modification site assignment

35

. To acquire the product-ion spectra, proteins are

first digested into peptides by site specific enzymes. Trypsin, used most often for
such digestion, is an endoproteinase that specifically cleaves the peptide bonds
containing lysine (Lys) or arginine (Arg) residues at the C terminus. Because the
average percentage of Lys and Arg in a protein sequence is about 5% and 6%
respectively, a reasonable amount of peptide fragments can be produced by
trypsin digestion. Some of the obtained peptides are multiply charged due to the
presence of basic residues Lys and Arg.
The peptide digest is separated by liquid chromatography to increase the
resolution of MS and concentrate the analytes before MS/MS analysis of the
peptides. If the peptides can be resolved by mass analysis and the sample is
sufficient for the entire analysis, the peptide mixture can be introduced by direct
infusion and the peptides of interest are isolated and analyzed.
20

In QIT, the peptide of interest is isolated by the first stage of mass analysis,
followed by CID to fragment the peptide. The obtained product ions are
sequentially scanned out and the product-ion spectrum is generated by recording
the m/z of each fragment ion relative to its intensity in the full mass range.
Figure 1.8. shows six possible types of fragment ions obtained from
dissociation at three different positions along the backbone during CID. The
sequence obtained from b ion-series is from the N terminus to the C terminus and
vice versa for the sequence obtained from the y-ion series. Therefore, b ions and
y ions obtained from CID are able to provide important sequence information of a
peptide. In addition, some fragments caused by the neutral loss of water or
ammonia from side chains are often observed in the product-ion spectrum of the
peptide. But these ions from neutral losses cannot provide information regarding
the peptide sequence.
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Figure 1.8. The types of the product ions generated by MS/MS

MS/MS and MSn analyses of a modified peptide in the ion trap allow for
determination of covalent modification to the peptide 36. The sequence ions containing
the covalently modified moieties can be inferred by their mass shift because the
modified residues have a common mass shift corresponding to their theoretical mass.
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The exact modified site of the moieties can be determined by characterizing the
modified sequence ions of the peptide in MSn analysis. In this dissertation, the
binding sites of cisplatin on cyt c, Mb, and Ub are determined by MS/MS and MS3
analyses.

1.3.6. Fourier transform mass spectrometry (FT-MS)
FT-MS was introduced in 1974 by Marshall and Comisarow

37

. The technique

provides unparalleled mass accuracy and resolution in mass spectrometry. Its mass
accuracy can reach 2 ppm and its resolution can reach 1e6 for ions below 500 m/z. Its
high mass accuracy and high resolution arise from the fundamental basis of FT-MS.
An ion in a magnetic field will take a circular trajectory, perpendicular to the
magnetic field. The circular motion of the ion is balanced by centrifugal force and
centripetal force. The balance of the two forces is described by Equation 3. The
rearrangement of Equation 3 gives Equation 4 38,39:

mv 2
= Bzv
r
Centrifugal
force

ω=

Equation (3)

v
z
= B
r m

Equation (4)

Centripetal
force

In these two equations, m and z is the mass and charge of the ion respectively, ν
is the ion velocity, B is the magnetic field strength, r is the radius of the circular
trajectory, and ω is the angular velocity of the ion motion. According to Equation 4,
the angular frequency ω of each ion is reversely related to the m/z of the ion in a fixed
magnetic field. Therefore, the m/z of the ion can be measured by measuring ω,
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cyclotron frequency, for that m/z value.
An ion can be excited by an external electric field of the same cyclotron
frequency ω of the ion. After such excitation, the kinetic energy of the ion increases,
thereby increasing the radius of its cyclotron trajectory. This phenomenon is called ion
cyclotron resonance (ICR). Because ions with the same m/z will be excited by the
same frequency, the ions with the same m/z will circulate on the same trajectory with
the same frequency in a packet. Therefore, ICR is used to excite ions. The first
application of ICR theory was by Hipple et al. in 1949 40.
Ion detection in FT-MS primarily involves two steps: ion excitation and detection
of the image current

38,39

. Figure 1.9. displays a schematic of a cylindrical ICR cell.

The top and bottom sections on the cylinder are the two sections for ion detection.
The side sections are the two sections used to excite the ions by an RF potential with a
broad range of frequencies.
All the ions in the ICR are excited simultaneously for detection by applying a RF
potential with constant amplitude and a broad range of frequencies to the excitation
plates for about 1 us. The application of the RF potential enables all the ions to
simultaneously gain kinetic energy and enlarge their radius of trajectory while in an
ion packet. When the ion packet is very close to one detection plate, their charge
causes electrons in the detection circuit to flow to that plate. When the packet
approaches the other plate, the electrons flow back through the detection circuit to that
plate. The continuously circular motion of the ions along their trajectory will generate
image current, oscillating at the same frequency as their cyclotron frequency. The
generated image current is detected by monitoring the current flow that is then
recorded as a function of time. The current signal at each specific time arises from the
23

sum of image currents for all the ion packets with a broad range of cyclotron
frequencies. A Fourier transform is used to convert the time-domain signal into a
frequency-domain signal to assign the intensity and the cyclotron frequency for each
individual ion packet to a specific m/z value based on Equation 4.
The repeated measurement of image current contributes to the high mass
precision of the technique. The narrower the peak is, i.e., the higher the resolution is.
However, the resolution of FT-MS is affected by the pressure in the cell, thus a high
vacuum (less than 10-9) is required.
The tremendous pressure difference between the ESI source and FT-MS makes it
difficult to use ESI as the ionization source for this technique. The coupling of the ESI
source with FT-MS is achieved by using several stages of differential pumping 41. The
performance is improved by coupling FT-MS with other mass analyzers (such as
LTQ). The coupling of the LTQ and FT-MS enables accumulation and collision
cooling of ions in the LTQ before entering FT-MS 32 .
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Figure 1.9. Schematic of a FT-MS instrument
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Chapter 2. Direct Determination of the Primary Binding
Site of Cisplatin on Cytochrome c by Mass Spectrometry

2.1. Introduction
Cisplatin is effective in the treatment of various cancers, particularly testicular
and ovarian cancers 1,2. In the body, cisplatin interacts with DNA and thereby induces
apoptosis in tumor cells

3,4

. Because blood plasma proteins are good nucleophiles for

cisplatin, they play an important role in transporting cisplatin to the tumor cells 5.
Unfortunately, some blood plasma protein–cisplatin binding is irreversible, which not
only renders cisplatin inactive but also allows it to accumulate in tissues and induce
side effects

6,7

. Exploration of protein-platinum metallodrug interactions provides

insight into both the transportation role of the blood plasma proteins that enables
therapeutic use and the irreversible binding that induces side effects. This knowledge
can be employed in the design of new therapeutic agents with increased effectiveness
and reduced side effects.

Pioneering work by Ivanov et al.

8

employed nuclear magnetic resonance

spectroscopy (NMR) to locate the binding sites of cisplatin on human serum albumin.
Recently,

X-ray crystallography elucidated the crystal structures of superoxide
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9

dismutase-cisplatin adducts

and lysozyme-cisplatin adducts

ionization mass spectrometry (ESI-MS)

11,12

10

. Electrospray

coupled with the development of

technologies for determining protein post-translational modifications

13

enabled

characterization of protein-Pt metallodrug interactions.

Gibson’s group first reported the studies of the ubiquitin-cisplatin interactions
using ESI-MS

14,15

. Subsequently, the binding site of cisplatin on transferrin was

determined by liquid chromatography tandem mass spectrometry (LC-MS/MS),
providing the basis for molecular modeling of the transferrin-cisplatin interactions
16,17

. In addition, the performances of matrix-assisted laser desorption/ionization mass

spectrometry (MALDI–MS) and ESI-MS were compared for the study of the
ubiquitin-Pt metallodrug interactions

18

. More recently, Dyson and his coworkers

19

reported a rapid top-down approach to determine the binding sites of Pt metallodrugs
on ubiquitin. Clearly, mass spectrometry has proven to be a powerful technique for
the study of the protein-Pt metallodrug interactions.

Cytochrome c (cyt c) is a small, well-characterized protein containing several
potential binding sites for Pt metallodrugs including methionines and histidines. Like
ubiquitin, cyt c is a common model protein that has been used to study the protein-Pt
metallodrug interactions by ESI-MS and MS/MS
described in the literature

20

20-22

. LC-MS/MS experiments,

, enabled the determination of the binding sites of

carboplatin on cyt c. Although Casini et al.

21

reported the formation of the cyt

c-cisplatin adducts using ESI-MS, they did not determine the binding site of cisplatin
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on cyt c. Recently, Casini et al.

22

reported a comprehensive study of the interactions

of Pt (II) iminoethers with cyt c including the determination of the primary binding
site of Pt (II) iminoethers on cyt c based on ESI-MS and NMR.

Assigning the location of a protein’s binding site(s) for Pt metallodrugs is
essential to better understanding the protein-Pt metallodrug interactions. This research
describes direct determination of the binding site(s) of cisplatin on cyt c via Fourier
transform mass spectrometry (FT-MS)

23

and tandem mass spectrometry (MSn). The

high resolution and high mass accuracy of FT-MS enable identification of different
fragments in the adduct digest from those in the free cyt c digest without need for a
sample purification step. MSn analyses of the unique fragments in the adduct digest
provide their structural information and enable the determination of the binding site(s)
of cisplatin based on the mass shift of b ions or y ions of the peptides in the
Pt-compound containing fragments
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, revealed by broader isotope distributions of

some product ions in their product-ion spectra 17.

2.2. Experimental
2.2.1. Materials
Horse heart cyt c, cisplatin, ammonium acetate (NH4OAc), and ammonium
bicarbonate were purchased from Sigma (St, Louis, MO). Sequencing grade modified
trypsin, methanol (HPLC grade), and acetic acid (HAc) (analytical grade) were
30

obtained from Fisher Scientific (Pittsburgh, PA). All chemicals were used directly
without further purification. Deionized water was used throughout the experiments.
The cyt c sequence is displayed in Figure 2.1.

Heme

1 Ac- GDVEKGKKIFVQKCAQCHTVEKGGKHKTGP

30

31

NLHGLFGRKTGQAPGFTYTDANKNKGITWK

60

61

EETLMEYLENPKKYIP GTKMIFAGIKKKTE

90

91

REDLIAYLKKATNE

104

Cyt c sequence 1-104

Figure 2.1. The cyt c sequence

2.2.2. Preparation of the cyt c–cisplatin adducts
100 μM cyt c was reacted with cisplatin at different molar ratios (cyt c:cisplatin
1:4, 1:8, 1:12, and 1:16) under native conditions in 5 mM NH4OAc aqueous solution
(pH 6.8) at 37 ℃ for different time in order to investigate the formation of the cyt
c-cislatin adducts by ESI-MS. The cyt c-cisplatin adducts used in protein digestion
were prepared by reacting 100 μM cyt c with cisplatin at 1:16 cyt c:cisplatin molar
ratio at pH 6.8, 37 ℃ for 24 h. Prior to ESI-MS, the cyt c solutions were diluted to
100 nM with a 30% MeOH–5 mM NH4OAc solution.

31

2.2.3. Protein digestion
The cyt c-cisplatin adducts in the 1:16 cyt c:cisplatin mixture were diluted to 20
μM with 50 mM NH4HCO3 (pH 7.8) and then subjected to trypsin digestion at a
protein to enzyme ratio of 50:1 (w/w) at 37 ℃ for 70 min. As a control, 20 μM free
cyt c was digested under the same conditions. Before ESI-MS analysis, the digest
solution was diluted to 5 μM with a 50% MeOH-0.1% HAc buffer.

2.2.4. ESI-MS analyses of the cyt c adducts
ESI-MS analyses of free cyt c and the cyt c-cisplatin adducts were carried out on
a quadrupole ion trap mass spectrometer coupled with a standard electrospray
ionization source (Finnigan LCQTM, San Jose, CA). The heated metal capillary was
maintained at 200 ℃. The spray voltage was set to 4.5 kV. Nitrogen was used as the
sheath gas and its flow rate was 30 units/min. The capillary voltage and the tube lens
voltage were held at 35 V and 10 V, respectively. The cyt c solutions were introduced
by direct infusion with a flow rate of 3 μL/min. Ion optics were tuned at 1766 m/z.
A mass range of 1500-2000 m/z was used to collect ESI-MS spectra. The ESI-MS
spectra were deconvoluted using MagTran software

25

. OriginPro8 (OriginLab

Corporation, Northampton, MA) was used to plot the data obtained in preparation of
the cyt c-cisplatin adducts.
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2.2.5. FT-MS, MS/MS and MS3 analyses
FT-MS, MS/MS, and MS3 analyses of the cyt c digests were carried out on a
Thermo Finnigan LTQ-FT system equipped with an Ion Max ion source (San Jose,
CA). The operating conditions of the ESI source were mentioned above. The digests
were introduced by direct infusion at 3 μL/min. Ion optics were tuned for the ions of
interest. FT-MS analyses of the free cyt c digest and the adduct digest in a mass range
of 500-2000 m/z were performed to identify unique fragments in the adduct digest.
Those fragments appearing uniquely in the FT-MS spectrum of the adduct digest were
subjected to MS/MS and MS3 in the linear ion trap. The isolation width was set to 5
m/z. Before collision induced dissociation (CID), the ions of interest were
accumulated for 150 to 500 ms to increase ion intensity. A normalized collision
energy (NCE%) of 30% was employed in MS/MS and MS3. The isotope distributions
of product ions were obtained by zoom scan. All product spectra were recorded in a
full mass range during the MS/MS and MS3 analyses of the digests. The product
spectra were replotted and labeled in Origin 6.0 (OriginLab Corporation,
Northampton, MA). ExPASy Proteomics Server was used to search the cyt c sequence
and to calculate the theoretical mass of the fragments in the adduct digest and the
product ions of the peptides involved.
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2.3. Results and Discussion
2.3.1. Preparation of the cyt c-cisplatin adducts
The formation of the cyt c adducts in three solutions, containing cyt c and
cisplatin at molar ratios of 1:4, 1:8 and 1:12 respectively, was examined at different
time intervals over 30 h in order to monitor the adduct formation. Throughout these
studies, 12604.3 Da is the primary adduct ion observed in the deconvoluted ESI-MS
spectra. This signal is assigned as monoadduct cyt c-Pt(NH3)2(H2O) because the
formation of the adduct results in a mass shift of 245.9 Da from free cyt c (measured
mass 12358.4 Da), which is close to the theoretical mass of Pt(NH3)2(H2O) (246.026
Da). No cyt c-Pt(NH3)2Cl is detected, indicating that the side chains of cyt c replace
one water in hydrolyzed cisplatin Pt(NH3)2(H2O)2 yielding cyt c-Pt(NH3)2(H2O)

18

.

For clarity, the charge states of the Pt compounds are omitted in this paper. The
formation of cyt c-Pt(NH3)2(H2O) is described by Equation 1:
⎯⎯
→ cytc − Pt ( NH 3 )2 ( H 2O) + H 2O
cytc + Pt ( NH 3 )2 ( H 2O) 2 ←⎯
⎯

Equation (1)

Because the signal of cyt c-Pt(NH3)2(H2O) covers over 90% of the signals of the
adducts in the three solutions, the percentage of cyt c-Pt(NH3)2(H2O) in the total cyt c
of each solution is used to represent the formed adducts. Figure 2.2. shows the
changes of the percentage of cyt c-Pt(NH3)2(H2O) in three solutions over 30 h.
Although more cyt c-Pt(NH3)2(H2O) appears in the solution with a higher cisplatin
concentration, the trends of the formation of cyt c-Pt(NH3)2(H2O) are similar in the
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three solutions. The percentage of cyt c-Pt(NH3)2(H2O) in all three solutions increases
sharply during the first 5 hours, and then increases gradually until 21 hours, after
which it remains constant indicating the attainment of equilibrium. In this research,
24h is used as the reaction time to prepare the cyt c-cisplatin adducts for protein

Percentage of cyt c-Pt(NH3)2(H2O) (%)

digestion.

0.7

1:12 Cyt c:cisplatin

0.6
0.5

1:8 Cyt c:cisplatin
0.4
0.3

1:4 Cyt c:cisplatin
0.2
0.1
0.0
0

5

10

15

20

25

30

Reaction Time (h)

Figure 2.2. The percentage of cyt c-Pt(NH3)2(H2O) in three cyt c-cisplatin solutions: ( ) 1:4
cyt c:cisplatin; () 1:8 cyt c: cisplatin; (

) 1:12 cyt c:cisplatin at different time intervals over 30

hours

Figure 2.3. shows the deconvoluted ESI-MS spectra of free cyt c and the cyt
c-cisplatin adducts prepared by reacting 100 μM of cyt c with cisplatin at different cyt
c:cisplatin molar ratios (1:8, 1:12 and 1:16) under native conditions for 24 h. Three
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groups of peaks are observed, arising from free cyt c, the 1:1 cyt c:cisplatin adducts
(monoadducts), and the 1:2 cyt c:cisplatin adducts (diadducts), respectively. In all of
these spectra, the diadduct signal is extremely low, indicating that monoadducts are
the major adducts. Besides the primary monoadduct cyt c-Pt(NH3)2(H2O), the other
monoadducts are assigned as cyt c-Pt(NH3), cyt c-Pt(NH3)2, cyt c-Na-Pt(NH3)2(H2O),
and cyt c-H2O-Na-Pt(NH3)2(H2O) corresponding to the small peaks at 12569.0,
12586.2, 12626.7, and 12644.3 Da. Because these spectra also indicate that the
largest amount of adducts are produced in the 1:16 cyt c-cisplatin solution, this
solution is selected for the preparation of the cyt c-cisplatin adducts for trypsin
digestion in the following studies.

Monoadducts
Diadducts

Cyt c

Relative Intensity (%)

100

A

F

80

1:16 Cyt c:cisplatin

60

1:12 Cyt c:cisplatin

40
20

C
B

H
DE G

1:8 Cyt c:cisplatin
Cyt c

0

12300 12400 12500 12600 12700 12800 12900 13000
Mass (Da)

Figure 2.3. Deconvoluted ESI-MS spectra of free cyt c and the cyt c-cisplatin adducts obtained
by incubating cyt c and cisplatin at different molar ratios for 24 h under native conditions. The
assignment of individual peaks: A) cyt c; B) cyt c-H2O; C) cyt c-(H2O)2; D) cyt c-Pt(NH3);

E) cyt c-Pt(NH3)2; F) cyt c-Pt(NH3)2(H2O); G) cyt c-Na-Pt(NH3)2(H2O);
H) cyt c-H2O -Na-Pt(NH3)2(H2O)
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2.3.2. Determination of the primary binding site of cisplatin on cyt c
2.3.2.1 Protein digestion
MSn analyses of smaller fragments arising from trypsin digestion of the cyt
c-cisplatin adducts provide information regarding the adduct structure. Because the
stable cyt c-cisplatin adducts were obtained under native conditions, trypsin digestion
was performed under native conditions in order to prevent dissociation of the
Pt-compounds from cyt c and cyt c fragments. A 50 mM NH4HCO3 aqueous solution
(pH 7.8) held at 37℃ was used for optimal conditions in trypsin digestion 26. Initially,
free cyt c was digested under the above conditions for 70 min to serve as the
experimental control. Figure 2.4. shows the FT-MS spectrum of the free cyt c digest,
which indicates a complete digestion of free cyt c. Small peptides with low charge
states from 1 to 3, located within 500-1200 m/z, give rise to the most abundant
signals.

Under the same conditions, the adduct solution prepared from 1:16 cyt c:cisplatin
mixture was digested. The FT-MS spectrum of the adduct digest is displayed in Figure
2.5. Figure 2.5. is compared with Figure 2.4. in detail in order to identify the new
digest fragments in the adduct digest. As indicated in Figure 2.5., the new fragments
in the mass range over 1000 m/z with high charges (+4 to +6) suggest partial
digestion of the adducts. Such partial digestion of the adducts likely arises because the
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cisplatin binding to cyt c results in a tighter folding of the cyt c. Although extension of
the digestion time permits a more complete digestion, it also results in the production
of additional fragments that increase the complexity of the resulting FT-MS and MSn
spectra. Therefore, the digestion time of the cyt c adducts was 70 min, the same as the
digestion time of free cyt c.

Further MSn analyses of the new fragments observed in the adduct digest
indicate that these fragments correspond to four multiply charged fragments listed in
Table 2.1, obtained by trypsin cleavage at two peptide bonds in the adducts. Of the
four fragments, two are Pt(NH3)2(H2O)-containing peptides and the other two are
heme-containing peptides. The product-ion spectra of these four fragments reveal the
primary binding site of cisplatin.

38

Figure 2.4. The FT-MS spectrum of the free cyt c digest

Figure 2.5. The FT-MS spectrum of the adduct digest
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Table 2.1. Four new fragments in the FT-MS spectrum of the adduct digest identified by
MS/MS and MS3 analyses

Fragments

The

fragments’

composition

#1

#2

#3

m/z of the

Calculated

Measured

fragments

mass

mass

(Da)

(Da)

Gly56-Glu104+ H2O

1507.7774+

+Pt(NH3)2(H2O)

1206.4235+

Asn54-Glu104+ H2O

1568.3114+

+Pt(NH3)2(H2O)

1254.8505+

Acety1-Gly1-Lys53+Heme

1593.5464+

6023.109

6027.112
Δm* =4.003

6265.247

6269.247
Δm =4.000

6369.124

1275.0375+

6370.184
Δm=1.060

1062.6976+
#4

Acetyl-Gly1-Lys55+Heme

1654.0774+
1323.4635+
1102.8876+

*Δm is mass deviation of measured mass from calculated mass.
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6611.262

6611.982
Δm = 0.720

2.3.2.2. Determination of the primary binding site from Fragment #1
and Fragment #2
MS/MS and MS3 analyses indicate both 1507.7774+ and 1206.4235+ ions arise
from Fragment #1. Figure 2.6. shows the product-ion spectrum from MS/MS of the
1507.7774+ ion, in which two abundant doubly charged fragment ions 1456.27 and
1558.18 appear. The total mass of the 1456.272+ and 1558.182+ ions is 6024.90 Da,
which has -2.21 Da mass difference from the mass of the parent ion 1507.7774+
(6027.11 Da), suggesting that 1507.7774+ primarily fragments at one position during
CID to produce the 1456.272+ and 1558.182+ fragment ions. MS3 analyses of both
fragment ions provide additional structural information. MS3 analysis of the 1456.272+
ion from the 1507.7774+ ion, Figure 2.7., indicates that the 1456.272+ ion corresponds
to a peptide with the sequence Met80-Glu104 (theoretical mass 2909.60 Da). The
1456.272+ ion has a mass deviation of 0.93 Da from the theoretical mass of
Met80-Glu104. Met80-Glu104 is at the C terminus of the cyt c sequence, suggesting
that the 1456.272+ and 1558.182+ ions arise from the cleavage of the Lys79~Met80
peptide bond.
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Figure 2.6. The product-ion spectrum of the MS/MS analysis of the 1507.7774+ ion and zoom
scans of the product ions 1456.272+ and 1558.182+

2+

The broader isotope distribution of the ion envelope at 1558.18

compared with

that at 1456.272+ in Figure 2.6. suggests 1558.182+ corresponds to a Pt-compound
containing fragment. Because Pt(NH3)2(H2O) is the primary Pt-compound bound to
cyt c, the peptide mass of 1558.182+ is estimated by subtracting the mass of
Pt(NH3)2(H2O) (246.03 Da) from the mass of 1558.182+ (2868.33 Da). The estimated
mass is very close to the mass of the peptide Gly56-Lys79 (theoretical mass 2867.48
Da) with a mass difference of 0.85 Da. The peptide sequence of 1558.182+ as
Gly56-Lys79 is consistent with the above result that 1558.182+ is produced by
cleaving the peptide bond Lys79~Met80 in Fragment #1. Some sequence ions of
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peptide Lys56-Met79 are also observed in the MS3 analysis of 1507.7774+ at
1558.182+, displayed in Figure 2.8. Consequently, the fragmentation of Fragment #1
produces two peptide fragments, the Pt(NH3)2(H2O) bound peptide Gly56-Lys79 and
the peptide Met80-Glu104. The formation of two peptide fragments in gas phase from
Fragment #1 suggests that one water molecule is associated with the peptide bond
Lys79~Met80. The peptide bond Lys79~Met80 is not cleaved in trypsin digestion
even after it is associated with one water molecule, suggesting the interactions
Pt(NH3)2(H2O) with the peptide Gly56-Glu104 results in a more stable Lys79~Met80
peptide bond.
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Figure 2.7. The product-ion spectrum of the MS3 analysis of the 1507.7774+ ion at m/z 1456.27.
The peptide sequence of the 1456.272+ ion : (Met80-Glu104) MIFAGIKKKTEREDLIAYLKKA
TNE
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In Figure 2.8., the 1531.642+ ion is the primary product ion produced by neutral
loss of two H2O and one NH3 from the 1558.182+ ion, indicating the peptide bonds in
the 1558.182+ ion are hard to break due to the Pt(NH3)2(H2O) binding. Most peaks are
enlarged 20 times in Figure 2.8. in order to display the sequence ions for the peptide
Gly56-Lys79 and the Pt-compound containing fragment ions (1383.45+, 1419.36+,
and 1952.82+). The strong intensity of y14+ (1679.82+) suggests that the peptide bond
Met65~Glu66 readily fragments. The calculated mass of the complementary ion of
y14+ is 1436.54 Da, which is close to the molecular mass of [b10+Pt(NH3)2(H2O)]+
(theoretical mass1435.62 Da). However, the 1383.45+ and 1419.36+ ions are observed
and assigned as the Pt-compound containing b10+ ions because neutral loss dominates
during fragmenting the 1558.182+ ion, indicated by the primary fragment ion
1531.642+ in Figure 2.8. Based on the assignments of the Pt-compound containing
fragment ions, the Pt compounds bind to one of the amino acid residues of the b10+
ion (Gly56-Met65), in which Met65 has highest affinity for the Pt(II) compounds.
Therefore, Met65 is the most probable binding site for Pt(NH3)2(H2O). Met65 is
located in the middle of the fragment Gly56-Lys79 and the tight interaction between
Pt(NH3)2(H2O) and Met65, contributes to strong peptide bonds in the MS3 analysis of
1507.7774+ at 1558.182+.
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Figure 2.8. The product-ion spectrum of the MS3 analysis of the 1507.7774+ ion at m/z
1558.18.The peptide sequence of the 1558.182+ ion: (Gly56-Lys79) GITWKEETLMEYLENPK
KYI PGTK

The MS/MS and MS3 analyses of Fragment #2 also suggest Met65 is the
Pt(NH3)2(H2O) binding site. The mass difference between Fragment #1 and Fragment
#2 is 242.135 Da, which is the mass of amino acid residues NK (theoretical mass
242.137 Da), suggesting that Fragment #2 is a Pt(NH3)2(H2O) bound peptide with a
sequence of Asn54-Glu104. The structure of Fragment #2 as the Pt(NH3)2(H2O)
bound Asn54-Glu104 is confirmed by the MS/MS analysis of the 1568.3114+ ion for
Fragment #2, which is shown in Figure 2.9. Similar to Figure 2.6., two
complementary fragment ions, 1456.362+ and 1679.272+, are observed in the MS/MS
analysis of the 1568.3114+ ion. Identical to Fragment #1, the 1456.362+ ion arises from
the peptide fragment Met80-Glu104. Figure 2.9. indicates that the 1679.272+ ion is a
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Pt(NH3)2(H2O) containing peptide fragment. Therefore, the appearance of the
1456.362+ and 1679.272+ ions confirms that Fragment #2 is a Pt(NH3)2(H2O) bound
peptide with a sequence of Asn54-Glu104. The binding site of Pt(NH3)2(H2O) is at the
peptide fragment Asn54-Lys79. In the residues from Asn54 to Lys79, Met65 is still
the most probable binding site for Pt(NH3)2(H2O).
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Figure 2.9. The product-ion spectrum of the MS/MS analysis of the 1568.3114+ ion and zoom
scan of the product ion 1679.272+

2.3.2.3. Identification of Fragment #3 and Fragment #4
Fragment #3 is represented by three ions 1593.5464+, 1275.0375+, 1062.6976+ and
Fragment #4 is also observed as three ions 1654.0774+, 1323.4635+, 1102.8876+ in
Figure 2.5. Figure 2.10. and 2.11. are the product-ion spectrum of the 1275.0375+ ion
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at Fragment #3 and the product-ion spectrum of the 1323.4635+ ion at Fragment #4,
respectively. Figure 2.10. and 2.11. have several common fragment ions, suggesting
that Fragment #3 and Fragment #4 have similar structures. The heme group is present
in both fragments according to the peak at m/z 617.27 in both spectra. Spectral
analyses of Figure 2.10. and 2.11. indicate that Fragment #3 is identified as a heme
containing peptide, the sequence of which is Acetyl-Gly1-Lys53, produced by
cleaving Lys53~Asn54 in trypsin digestion. Fragment #4 is identified as a heme
bound peptide, Acetyl-Gly1-Lys55, produced by cleaving the peptide bond at
Lys55~Gly56 in trypsin digestion. Therefore, Fragment #3 is complementary to
Fragment #2 and Fragment #4 is complementary to Fragment #1 according to the cyt
c sequence, suggesting the cleavage mainly occurred at two positions (Lys53~Asn54
and Lys55~Gly56 ) in trypsin digestion of the cyt c adduct. The results of the MSn
analyses of the four fragments indicate that Met65 is the primary binding site of
cisplatin on cyt c.
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Figure 2.10. The product-ion spectrum of the MS/MS analysis of the 1275.0375+ ion. The
peptide sequence of the 1275.0375+ ion: (Acetyl-Gly1-Lys53) Acetyl-GDVEKGKKIFVQKCA
QCHTVEKGGKHKTGPNLHGLFGRKTGQAPGFTYTDANK
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Figure 2.11. The product-ion spectrum of the MS/MS analysis of the 1323.4635+ ion. The
peptide sequence of the 1323.4635+ ion: (Acetyl-Gly1-Lys55) Acetyl-GDVEKGKKIFVQKCAQ
CHTV EKGGKHKTGPNLHGLFGRKTGQAPGFTYTDANKNK
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2.4. Conclusions
This research illustrates a mass spectrometric method for the direct determination
of the primary binding site of cisplatin on cyt c. ESI-MS data reveal that the cyt
c-Pt(NH3)2(H2O) monoadduct is the primary adduct produced by the cyt c-cisplatin
interactions under native conditions in 30 h. Four new fragments appear in the adduct
digest compared with the free cyt c digest. The complete identification of these four
fragments suggests that the cyt c adducts are cleaved mainly at two positions
Lys53~Asn54 and Lys55~Gly56 by trypsin. These data support the assignment of
Met65 as the primary binding site of cisplatin on cyt c. Therefore, the monoadduct cyt
c-Pt(NH3)2(H2O) arises from covalent interactions between Pt(NH3)2(H2O) and Met65
in cyt c. The high specificity of this MS method enables direct determination of the
primary cisplatin binding site without need for additional sample purification. The
successful identification implies that this mass spectrometric approach based on
FT-MS and MSn can be useful in the exploration of the binding site(s) of the Pt
metallodrugs on other proteins.
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Chapter 3. Myoglobin Denaturation

3.1. Introduction
Cisplatin is an effective anti-tumor drug, which can disrupt DNA replication and
stop cell division by binding to DNA 1. Because platinum (II) is a soft metal ion,
cisplatin also interacts with blood plasma proteins especially those sulfur-containing
proteins. On the one hand, the blood plasma protein-cisplatin interactions are believed
to contribute to drug efficacy because the formed adducts might serve as a Pt reservoir
for DNA 2. On the other hand, irreversible interactions between blood plasma proteins
and cisplatin not only decrease drug efficacy but also lead to side effects 3. Therefore,
it is important to determine the cisplatin binding sites on proteins in order to
understand the principles that govern adduct formation and the roles that proteins play
in the therapeutic profile of cisplatin.

Myoglobin (Mb) is used as a model protein to study such protein interactions
with cisplatin. Mb has a molecular weight of 17, 567 Da and contains a polypeptide
chain of 153 amino acids and a heme prosthetic group. Under native conditions, the
secondary structures of Mb including eight helices (A-H), turns, and loops are tightly
packed, leaving a hydrophobic cleft at helices C, E, and F for the heme moiety 4. The
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entire polypeptide is folded into a globular structure with all the hydrophobic residues
buried inside and most of the polar residues exposed to the environment 5.

Electrospray ionization mass spectrometry (ESI-MS) and tandem mass
spectrometry (MS/MS) are utilized to determine the binding sites of cisplatin on Mb.
Because peptides are more suitable for MS/MS than proteins, Mb adducts are digested
into peptides prior to MS/MS. Proteins are often digested by fast and simple
in-solution protein digestion. However, Mb can not be digested by this approach
because Mb is a globular protein and the cleavable sites of Mb are buried inside the
Mb structure. Therefore, Mb denaturation is required to disrupt the secondary and
tertiary structures in order to expose the potential cleavage sites to the digestion agent
6

.

This chapter describes the selection and optimization of an approach used to
denature the tightly folded Mb. Thermal denaturation and organic-aqueous solvent
denaturation are used with apo-Mb and the Mb-cisplatin adducts. The conditions of
the selected approach are optimized in order to enable efficient protein digestion.

3.2. Experimental
Mb-cisplatin adducts were prepared by incubating 100 μM Mb with 600 μM
cisplatin under 37℃ at pH 6.8 for 24 hour. In all the experiments, free Mb and the
Mb-cisplatin adducts were digested by trypsin at a protein/enzyme (w/w) ratio of 50:1.
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The protein denaturation method was preliminarily investigated with free Mb. After
preliminary investigation, the method was applied to the Mb-cisplatin adducts.

A 25 mM NH4HCO3 aqueous solution was used as the buffer for protein
digestion under native conditions and thermal denaturation of proteins. In protein
denaturation by mixed-organic solvents, mixtures of different percentages (50%, 60%,
and 70%) of methanol and 25 mM NH4HCO3 were used as the denaturation solutions.
Mb and Mb adducts are denatured by a 4-fold volume of the denaturing solutions.
After Mb denaturation, the denatured Mb solutions were subjected to trypsin digestion.
The obtained digests were diluted to 5 μM of the total Mb concentration with 50%
MeOH-0.3% HAc solution for ESI-MS analysis on a quadrupole ion trap mass
spectrometer (Finnigan LCQTM, San Jose, CA).

3.3. Results and Discussion
3.3.1. Tryptic digestion of free Mb under native conditions
Free Mb was digested by trypsin under native conditions as a control to compare
with the results of trypsin digestion after Mb denaturation. Figure 3.1. shows the
ESI-MS spectrum of the Mb digest obtained by incubating free Mb with trypsin for 21
h under native conditions at 37℃. In Figure 3.1, the peak at m/z 616.2 corresponds to
the heme group. The peaks from m/z 848.6 to m/z 1883.8 arise from free Mb without
the heme group with the charge states from 20 to 9, suggesting Mb is resistant to
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trypsin digestion under native conditions. This is because the structure of Mb is very
compact under native conditions and the cleavage sites are shielded inside the
hydrophobic core. Thus, protein denaturation was performed to disrupt the 3-D
structure of Mb and expose the cleavage sites.
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Figure 3.1. The native Mb digest after tryptic digestion for 21 h

3.3.2. Thermal denaturation
Proteins can be denatured by thermal denaturation, which is performed simply by
heating up the sample solution for a few minutes to increase the kinetic energy of the
protein. At a higher temperature, the bond vibration inside the proteins becomes more
rapid and violent, leading to disruption of high-order protein structures and protein
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denaturation 7. Free Mb and Mb-cisplatin adducts were denatured under 90℃,
according to Park et al.7 During thermal denaturation, protein aggregation was
observed in both free Mb and the Mb-cisplatin adduct solutions. The longer the
incubation time was, more aggregates were observed. Because there was little protein
aggregation observed within the first 20 min, 20 min was selected as the incubation
time for thermal denaturation to prevent protein aggregation.

After thermal denaturation for 20 min, both free Mb and the Mb-cisplatin
adducts were subjected to trypsin digestion. Figure 3.2. and Figure 3.3. show the
ESI-MS spectra of the digests of thermally denatured free Mb and the Mb-cisplatin
adducts after 17 h of trypsin digestion, respectively. In the ESI-MS spectra, the peaks
at different m/z ratios arise from the components in the solutions and the intensity of
each peak indicates the abundance of the corresponding component in the solutions.
The abundant free Mb peaks in Figure 3.2. indicate that most Mb were not digested.
Although there were more peptide peaks observed in the adduct digest in Figure 3.3.,
the peak envelopes arising from free Mb and the Mb-cisplatin adducts were still
abundant. It was decided that thermal denaturation under the conditions used in this
research was unable to denature the Mb-cisplatin adducts sufficiently for protein
digestion.

55

1305.00

95

1212.00

1542.20

90
85
80
1131.20
75
70

60

1696.33

55

1060.53

50
45
1884.73
40
35
30
943.67

25

804.40

616.47
20

998.27
909.20

748.60

15
1432.27

835.27

10
5

141.93 265.20

355.27 411.33

1861.27
1603.07

1838.07

1600

1800

1952.87

557.27

0
200

400

600

800

1000
m/z

1200

1400

2000

Figure 3.2. The free Mb digest obtained by trypsin digestion for 17 h after thermal denaturation
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3.3.3．Protein denaturation by a mixed methanol-aqueous solvent
Chemical denaturation enables a complete protein denaturation using 8 M urea or
6 M guanidine HCl as denaturing reagents 6. However, the reagents used not only
increase the complexity of the sample but also are incompatible with ESI-MS. Sample
purification is often required to remove the added chemicals before ESI-MS.

Russell’s group demonstrated successful protein denaturation using a mixed
organic-aqueous solvent 8. Methanol and acetonitrile are often used in the mixed
solvent system for protein denaturation and the solvents for ESI-MS. Because the
nitrile group in acetonitrile can displace Pt moieties on the Mb-cisplatin adducts and
the hydroxy group in methanol does not interrupt the Mb-cisplatin interactions,
methanol is used as the organic solvent to denature Mb.

It was reported by Kamatari et al.

9

that the tertiary structure of free Mb was

destroyed when the methanol concentration was above 30%. When Mb was in 50%
MeOH solvent, more than one denatured state was present besides the intermediate
state (IM), which has similar helical content to the native Mb. The existence of other
states than the IM state suggests the change in the secondary structure of free Mb.
Therefore, 50% MeOH, 60% MeOH, and 70% MeOH were used to denature Mb
before trypsin digestion. In these three mixed organic-aqueous solvents, 25 mM
NH4HCO3 was added in order to control ionic strength of the solutions.

Three Mb solutions were denatured by 50% MeOH, 60% MeOH, and 70%
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MeOH, respectively, followed by trypsin digestion for 75 min. Figures 3.4., 3.5., and
3.6. show the mass spectra obtained for the Mb digests of these three solutions.
Comparing these three spectra with Figures 3.1. and 3.2., it is obvious that no free Mb
peaks were observed. All the peaks arise from peptides, suggesting the Mb solutions
were effectively denatured by the MeOH-aqueous solvents prior to trypsin digestion.
Only 75 min was needed to fully digest Mb in each solvent (50% MeOH, 60%MeOH
and 70%MeOH), indicating the activity of trypsin was not significantly influenced by
a high organic content 8. More abundant peptide fragments are observed in the two
spectra, Figure 3.5. and Figure 3.6., than in Figure 3.4., indicating that 60% MeOH
and 70% MeOH are more effective than 50% MeOH for the denaturation of Mb.

In order to fully denature the Mb-cisplatin adducts, 70% MeOH with 25 mM
NH4HCO3 is used as the buffered denaturation system. After denaturation, the adducts
are digested by trypsin for 75 min. The digest was analyzed by ESI-MS, yielding the
mass spectrum shown in Figure 3.7. All the peaks correspond to peptides,
demonstrating the effectiveness of the 70% MeOH -25mM NH4HCO3 solvent system
for the denaturarion of Mb. Therefore, the 70% MeOH-25mM NH4HCO3 solvent is
selected and used as the denaturation buffer to denature the globular protein Mb and
the Mb adducts in subsequent studies.

58

1022.67

100
95
90
85
80
75
70
818.33

Relative Abundance

65
60
55

1135.73

50
45
40

1362.93

35

1271.67

1421.60

30
908.47

25

1705.67

20
762.07

15

5

1588.73

682.07
618.87

10

1775.07

195.27 315.00 471.27

0
200

400

600

800

1000
m /z

1200

1400

1600

1800

2000

Figure 3.4. The Mb digest obtained by trypsin digestion after denaturation in a 50%
MeOH-25mM NH4HCO3 solvent
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Figure 3.5. The Mb digest obtained by trypsin digestion after denaturation in a 60%
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Figure 3.6. The Mb digest obtained by trypsin digestion after denaturation in a 70%
MeOH-25mM NH4HCO3 solvent
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3.4. Conclusions
Both thermal denaturation and the methanol-aqueous solvent denaturation were
tested for their suitability to the denaturation of Mb for trypsin digestion. Thermal
denaturation is inapplicable because it is not sufficient for the subsequent digestion.
Protein aggregation is also a problem in thermal denaturation. By contrast, the
methanol-aqueous solvent approach efficiently denatures Mb. The Mb solutions
denatured by 50% MeOH, 60% MeOH, and 70% MeOH, all can be digested in only
75 min with trypsin. According to the ESI-MS spectra, there were more peptides in
the solutions denatured by 60% MeOH and 70% MeOH than the solution denatured
by 50% MeOH. In subsequent work in this lab, the 70% MeOH-25mM NH4HCO3
solvent was used to denature the Mb-cisplatin adducts for trypsin digestion and
satisfactory results were obtained. The 70% MeOH--25mM NH4HCO3 aqueous
solvent is used to denature Mb, the Mb adduct, ubiquitin (Ub), and the Ub adducts in
this dissertation.
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Chapter 4. A Mass Spectrometric
Comparison of the Interactions of Cisplatin
and Transplatin with Myoglobin

4.1. Introduction
Cisplatin [cis-diamminedichloroplatinum (II)] is a successful anticancer drug,
able to form intrastrand crosslinks with adjacent guanine residues in DNA and induce
apoptosis of cancer cells 1. In contrast, transplatin [trans-diamminedichloroplatinum
(II)], the geometric isomer of cisplatin, has no anticancer activity because it is unable
to form the intrastrand crosslinks with DNA 2. Although the cytotoxicity of cisplatin
arises from the DNA-cisplatin interactions, blood plasma protein-cisplatin interactions
are believed to play important roles in the efficacy of cisplatin as an anticancer drug.
A higher level of human serum albumin (HSA) enabled better treatment of patients 3,4
because the formation of HSA-cisplatin adducts might be responsible for the
transportation of cisplatin to DNA, suggested by model studies with small molecules 5.
Unfortunately, the irreversible binding of cisplatin to the blood plasma proteins
induces side effects 6.

Because blood plasma protein-Pt metallodrug interactions contribute to both
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drug efficacy and toxicity, nuclear magnetic resonance spectroscopy (NMR) 7, X-ray
crystallography 8, and mass spectrometry (MS)

9,10

have been employed to enhance

our understanding of the protein-Pt metallodrug interactions. Although such studies
have improved our knowledge regarding the protein-Pt metallodrug interactions, little
is known about the similarities and differences between the interactions of cisplatin
and transplatin with proteins. Previous studies focused on the interactions of cisplatin
and transplatin with ubiquitin indicated that cisplatin and transplatin have distinctly
different interactions with ubiquitin

11

. That report also provided preliminary

information on the kinetics of cisplatin and transplatin interactions with Mb 11.

Myoglobin (Mb) is a globular protein, consisting of a heme and a polypeptide of
153 amino acid residues. Under physiological conditions, over 70% of the
polypeptide backbone is folded into alpha helices and the folding of the entire Mb
polypeptide leads to a tight globular structure with the interior almost filled with
nonpolar residues. There are several potential binding sites for Pt metallodrugs on Mb
including 2 Met and 11 His

12

. In order to gain insights into the interactions of

cisplatin and transplatin with such globular proteins in biological fluids, the
interactions of cisplatin and transplatin with myoglobin are compared in detail in this
research. First, the kinetics of the Mb-cisplatin and Mb-transplatin interactions is
studied by monitoring the interactions over 30 h by electrospray ionization mass
spectrometry (ESI-MS). Subsequently, the formed Mb-cisplatin and Mb-transplatin
adducts are compared. Furthermore, the binding sites of cisplatin and transplatin are
determined based on the previously reported approach
64

13

to elucidate the binding

mode of Mb with cisplatin and transplatin. Finally, the stability of the Mb-cisplatin
and Mb-transplatin adducts are evaluated by reacting the Mb-cisplatin and
Mb-transplatin adducts with 5’-guanosine monophosphate (GMP), respectively.

4.2. Experimental
4.2.1. Materials
Cisplatin, transplatin, horse heart myoglobin, ammonium acetate (NH4OAc),
ammonium bicarbonate, and guanosine 5’-monophosphate (GMP) disodium salt were
purchased from Sigma (St. Louis, MO). Sequencing grade modified trypsin, methanol
(HPLC grade), and acetic acid (analytical grade) were obtained from Fisher Scientific
(Pittsburgh, PA). All reagents were used as purchased. Figure 4.1. shows the structure
of cisplatin, transplatin, guanosine 5’-monophosphate, and the Mb sequence 12.
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Figure 4.1. The structures of cisplatin, transplatin, and guanosine 5’-monophosphate and the
Mb sequence. The residues in the same helices are underlined and given in the same
parentheses.

4.2.2. The kinetics studies of Mb-cisplatin and Mb-transplatin
interactions
100 μM Mb was reacted with cisplatin (or transplatin) at a Mb:cisplatin (or
Mb:transplatin) molar ratio of 1:6 in a 5 mM NH4OAc solution (pH 6.8) at 37℃.
Aliquots of the Mb-cisplatin and Mb-transplatin solutions were withdrawn and
examined by ESI-QITMS (LCQTM, Thermo Finnigan, San Jose, CA), described below,
at selected times over a 30 h period. Prior to ESI-QITMS, each solution was diluted to
500 nM with a 50% MeOH-0.3% HAc solution in order to denature Mb and adjust
charges on the Mb species so that mass to charge ratios (m/z) of the Mb species were
within the mass range of the ion trap. The percentage of each species in the solution
was estimated by the ratio of the peak area of each species to the sum of the peak
areas of all the species. The plot of the percentage of each Mb species in the solution
versus the reaction time yielded the kinetics plot.
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4.2.3. The digestion of Mb-cisplatin and Mb-transplatin adducts
Mb-cisplatin and Mb-transplatin adducts were prepared by allowing the reactions
described above to proceed for 27 h. The obtained Mb adducts and free Mb were
digested under the same conditions. Prior to trypsin digestion, all the Mb solutions
were denatured by mixing the Mb solutions with a 4-fold volume of a denaturing
solution, consisting of 70% MeOH and 25 mM NH4HCO3. After denaturation for 10
min, free Mb and the Mb adducts were digested by trypsin at a protein to enzyme
ratio of 50:1 (w/w) under 37℃ for 75 min. The obtained digests were diluted with the
same volume of the 50% MeOH-0.3% HAc solution before ESI-QITMS.

4.2.4. Reactions of the Mb-cisplatin and Mb-transplatin adducts with
5’-GDP
The Mb-cisplatin and Mb-transplatin adducts prepared under the same conditions
as those used for protein digestion in 4.2.3. were thoroughly desalted by Microcon
YM-3 centrifugal filter devices (Millipore, Billerica, MA). The desalted Mb-cisplatin
and Mb-transplatin adducts were reacted with GMP (5 mM) at molar ratio of 1:5 (the
Mb adducts:GMP) under pH=6.8, 37℃. The formation of the Mb-GMP adducts was
monitored over 3 days by ESI-QITMS. The percentage of each Mb species in the
solution was estimated by the ratio of the peak area of each species to the total peak
areas of all the Mb species.
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4.2.5. ESI-MS and MSn
The reactions of cisplatin and transplatin with Mb and the reactions of the
Mb-cisplatin and Mb-transplatin adducts with GMP were monitored on a quadrupole
ion trap mass spectrometer equipped with a standard electrospray ionization source
(LCQTM, Finnigan, San Jose, CA). The spray voltage applied was 4.0 kV and the
temperature of the heated metal capillary was 200℃. The sample was injected by
direct infusion at a flow rate of 3 μL/min by a syringe pump. The flow rate of sheath
gas (nitrogen) was 30 units/min. The capillary voltage and the tube lens voltage were
held at 35 V and 10 V, respectively. The ion injection time was 5 ms. ESI-MS spectra
were recorded in the range of m/z 650-2000.

The free Mb digest and the adduct digests were analyzed on a hybrid linear ion
trap-Fourier transform mass spectrometer system equipped with an Ion Max ion
source (LTQ-FT, Thermo Finnigan, San Jose, CA). The conditions of the ion source
were described above. All the digests were analyzed by FT-MS identify ions
characteristic of the adducts. The fragments observed only in the adduct digests were
further analyzed by MS/MS and MS3 on the linear ion trap to provide additional
structural information. The isolation width was set at 5 m/z and 35% of normalized
collision energy (NCE%) was applied during collision induced dissociation (CID).
The isotope distributions of the product ions were acquired by zoom scan. All the
product-ion spectra were recorded in a full mass range. In spectral analysis, ExPASy
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Proteomics Server was used to search the Mb sequence and calculate the theoretical
mass of b ions and y ions for the peptides of interest. The data were plotted by
OriginPro 8 software (OriginLab Corporation, Northampton, MA).

4.3. Results and Discussion
4.3.1. The kinetics of the Mb-cisplatin and Mb-transplatin
interactions
The interactions of cisplatin and transplatin with Mb at Mb:cisplatin and
Mb:transplatin molar ratio of 1:6 respectively were monitored by ESI-QITMS over 30
h. Monoadducts (1:1 Mb-cisplatin and 1:1 Mb-transplatin adducts) and diadducts (1:2
Mb-cisplatin and 1:2 Mb-transplatin adducts) are the primary adducts observed in the
Mb-cisplatin and Mb-transplatin solutions. Figure 4.2a. and Figure 4.2b. show the
percentage change of each Mb species in the Mb-cisplatin and Mb-transplatin
solutions over 30 h, respectively.

Comparison of Figure 4.2a. and Figure 4.2b. indicates that the adduct formation
in the Mb-cisplatin interactions is faster than in the Mb-transplatin interactions. In
Figure 4.2a., the percentage of the 1:1 Mb-cisplatin adducts increases steeply and
reaches 40% in 6 h. However, Figure 4.2b. shows 12 h was used to produce the
similar amount of 1:1 Mb-transplatin adducts. For the diadducts, 1:2 Mb-cisplatin
adducts are observed at 9 h in Figure 4.2a., while 1:2 Mb-transplatin adducts are
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observed at 12 h in Figure 4.2b. In addition, Figure 4.2b. shows that the
Mb-transplatin interactions attain equilibrium in 24h because both 1:1 Mb-transplatin
adducts and 1:2 Mb-transplatin adducts remain constant after 24 h. But this is not the
case for the Mb-cisplatin interactions because the percentage of 1:2 Mb-cisplatin
adducts continues to increase slowly after 30 h. 1:3 Mb-cisplatin adducts will be
observed after a longer reaction time. In this research, the Mb-cisplatin and
Mb-transplatin interactions were allowed to proceed for 27 h to prepare the
monoadducts and the diadducts.
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Figure 4.2. The kinetics plots for the Mb-cisplatin and Mb-transplatin solutions obtained by
monitoring the percentages of the Mb species in the respective solutions as a function of
time:(a) The Mb-cisplatin solution; (b) The Mb-transplatin solution

4.3.2. The Mb-cisplatin and Mb-transplatin adducts
Figure 4.3. shows the deconvoluted ESI-QITMS spectra of free Mb and the
Mb-cisplatin and Mb-transplatin adducts obtained by reacting Mb with cisplatin and
transplatin for 27 h. As shown in Figure 4.3, the formation of the monoadducts
(measured mass 17, 182 Da) and the diadducts (measured mass 17, 409 Da) leads to
228 and 455 Da of mass increase from free Mb (measured mass 16, 954 Da),
suggesting Pt(NH3)2 (theoretical mass 228.016 Da) is the Pt compound that interacts
with Mb. For clarity, the charge states of the Pt compounds are not indicated.

71

In the first 4 h of the Mb-transplatin interactions, the peak corresponding to
monoadduct Mb-Pt(NH3)2Cl is observed. However, the peak corresponding to the
monoadduct Mb-Pt(NH3)2 was the only peak observed in the first 4 h of the
Mb-cisplatin interactions, indicating faster formation of Mb-Pt(NH3)2 in the
Mb-cisplatin interactions 14. The different speed in the formation of the monoadducts
Mb-Pt(NH3)2 for the Mb-cisplatin and Mb-transplatin interactions might arise from
the different arrangement of two chlorides for cisplatin and transplatin. Two chlorides
in cisplatin are adjacent to each other and this arrangement is probably more favorable
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Figure 4.3. Deconvoluted ESI-QITMS spectra of free Mb and the Mb-cisplatin and
Mb-transplatin adducts obtained by reacting Mb with cisplatin and transplatin for 27 hours
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4.3.3. Determination of the cisplatin and transplatin binding sites on
Mb
Determination of the binding sites of cisplatin and transplatin on Mb provides
insights into the binding modes of Pt(NH3)2 with Mb for the Mb-cisplatin and
Mb-transplatin interactions. In this research, the binding sites of cisplatin and
transpaltin are determined using our previously reported mass spectrometric
approach13.

4.3.3.1. The digestion of the Mb-cisplatin and Mb-transplatin adducts
The Mb-cisplatin and Mb-transplatin adducts were subjected to trypsin digestion
to obtain smaller fragments for MSn analyses. Free Mb was digested in parallel to
serve as the control. According to the results of Chapter 3, the 70% MeOH-25mM
NH4HCO3 solvent is used to denature Mb, the Mb-cisplatin adducts, and the
Mb-transplatin adducts before trypsin digestion for 75 min.

4.3.3.2. FT-MS analyses of the digests
FT-MS analyses were carried out to investigate the fragments in the digests of
free Mb, the Mb-cisplatin adducts, and the Mb-transplatin adducts. Figure 4.4., 4.5.,
and 4.6. are the FT-MS spectra of the digests of free Mb, the Mb-cisplatin adducts,
and the Mb-transplatin adducts, respectively. From appearance, the three spectra are
quite alike. Detailed examination of the three spectra indicates most fragments are
observed at m/z over 800 with high charge states ranging from 5+ to 8+, suggesting
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partial digestion of free Mb and the Mb adducts. The FT-MS spectra of the adduct
digests were compared with that of the free Mb digest in order to identify the unique
fragments in the adduct digests. The comparison indicates that most fragments in the
three digests are common based on their m/z and their charge state distributions.

The peaks corresponding to two fragments 1313.275+ and 1316.685+ are only
observed in the FT-MS spectra of the adduct digests, indicated by the expanded
FT-MS spectra of the free Mb digest, the Mb-cisplatin adduct digest, and the
Mb-transplatin adduct digest in Figure 4.7., 4.8., and 4.9., respectively. Surprisingly,
the peak envelops corresponding to the 1313.275+ and 1316.685+ ions are observed in
both Figure 4.8. and Figure 4.9.

The MS/MS spectra of the 1313.275+ and 1316.685+ ions are displayed in Figure
4.10. and Figure 4.11., respectively. The 1313.275+ and 1316.685+ ions are of similar
structure and have the identical peptide sequence because most peaks in the
product-ion spectrum of the 1313.275+ ion (Figure 4.10.) are also observed in the
product-ion spectrum of the 1316.685+ ion (Figure 4.11.). According to 17.05 Da mass
difference between the 1313.275+ and 1316.685+ ions and the MS/MS and MS3
analyses of the 1313.275+ and 1316.685+ ions in the two adduct digests, the 1313.275+
and 1316.685+ ions are identified as Pt(NH3) and Pt(NH3)2 bound peptides
His97-Gly153 respectively. Therefore, the characterization of the 1313.275+ and
1316.685+ ions in the adduct digests reveals one common binding site of cisplatin and
transplatin on Mb. Because the isotope distribution of the 1316.685+ ion is overlapped

74

with the isotope distribution of the peptide Leu32-Lys78 (1317.484+) in the FT-MS
spectra of both the adduct digests, the product-ion spectra of the MS/MS and MS3
analyses of the 1313.275+ ion are displayed to show the results for the determination
of the common binding site of cisplatin and transplatin on Mb.
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Figure 4.10. The product-ion spectrum of the 1313.275+ ion. The peptide sequence of the
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4.3.3.3. Identification of the peptide sequence of the 1313.275+ ion
The structure of the 1313.275+ ion as a Pt(NH3) bound peptide His97-Gly153 is
identified by the assigned sequence ions (b3+, y6+, y8+, y272+, y312+, and y342+) and two
Pt-containing fragment ions (1542.004+and 1570.454+) in the product-ion spectrum of
the MS/MS analysis of the 1313.275+ ion, Figure 4.10.

(I) The abundant sequence ions y272+, y312+ and y342+

The y272+, y312+, and y342+ ions in Figure 4.10. are assigned by the MS3 analyses of the
1313.275+ ion at these three ions. The product-ion spectra of MS3 analyses of the
1313.275+ ion at the y272+, y312+, and y342+ ions are displayed in Figure 4.12., 4.13., and
4.14., respectively. The peaks corresponding to the y272+ and y312+ ions are abundant in
the product-ion spectrum of the MS3 analysis of the 1313.275+ ion at y342+, Figure
4.14., suggesting that the sequence of the y342+ ion includes the sequences of the y272+
and y312+ ions. Similarly, the peak corresponding to the y272+ ion is intense in the
product-ion spectrum of the MS3 analysis of the 1313.275+ ion at the y312+ ion, Figure
4.13. Meanwhile, other y ions from y7+ to y11+ of the peptide His97-Gly153 are also
observed in the MS3 analyses of the 1313.275+ ion at the y272+and y312+ ions which
confirm the peptide sequence of the 1313.275+ ion as His97-Gly153. Significantly, the
identification of the intense y ions, y272+, y312+, and y342+, indicates that Pt(NH3) in the
1313.275+ ion is not attached to the amino acid residues from Pro120 to Gly153. In
addition, the abundance of the y272+ and y312+ ions in Figure 4.10. might arise from
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selective cleavage at Asp122~Phe123 and Asp126~Ala127 due to “aspartic acid
effect” 15. “Proline effect”15 leads to the selective cleavage at His119~Pro120 during
the MS/MS analysis of the 1313.275+ ion, yielding the abundant y342+ ion in Figure
4.10.
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Figure 4.12. The product–ion spectrum of the MS3 analysis of the 1313.275+ ion at the y272+ ion.
The peptide sequence of the y272+ ion: AQGAMTKALELFRNDIAAKYKELGFQG
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Figure 4.14. The product–ion spectrum of the MS3 analysis of the 1313.275+ ion at the y342+ ion.
The peptide sequence of the y342+ ion: PGDFGADAQGAMTKALELFRNDIAAKYKELGFQG
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(II) The abundant Pt-containing ions

Two abundant ions at m/z 1542.00 and 1570.45 are two Pt-containing fragment
ions with charges states of 4+ according to their charge state distributions in Figure
4.15. Several y ions in Figure 4.15. including the y272+, y312+, and y342+ ions are
observed in the product-ion spectra of the MS3 analysis of the 1313.275+ ion at m/z
1542.00 and 1570.45, which are displayed in Figure 4.16. and Figure 4.17., suggesting
that the 1542.004+ and 1570.454+ ions correspond to Pt bound y ions. The mass
difference between the 1542.004+ and 1570.454+ ions is 113.80 Da, which is the
residue mass of Ile/Leu. The 1542.004+ and 1570.454+ ions are produced by losing
fragments with total mass of 398.35 and 284.55 Da respectively from the 1313.275+
ion during CID, which are close to theoretical mass of [b3+NH3]+ (396.27 Da) and
[b2+NH3]+ (283.19 Da) respectively. The peak corresponding to the b3+ ion is
observed at m/z 379.27 in Figure 4.10. Therefore, the 1542.004+ and 1570.454+ ions
are assigned as [y54+Pt]4+ and [y55+Pt]4+ produced by cleaving the peptide bonds at
Ile99~Pro100 and Lys98~Ile99 combined with losing the NH3 ligand on the Pt(NH3)
compound during the MS/MS analysis of the 1313.275+ ion. The high intensity of the
1542.004+ and 1570.454+ ions also indicates selective cleavage at Ile99~Pro100 and
Lys98~Ile99 due to the two basic residues, Pro100 and Lys98

15

. Consequently, the

analysis of the 1542.004+ and 1570.454+ ions further confirms the structure of the
1313.275+ ion as a Pt(NH3)-bound peptide His97-Gly153.

82

60

1542.26 1542.76

80
Relative Intensity (%)

Relative Intensity (%)

80

1542.98

1542.04

40

20

0
1541

1542

1570.78
1570.02
1570.52

100

1542.52

100

1543
m/z

1544

1570.30
1570.34

60

40

20

0
1569

1545

1570

1571

1572

1573

1574

m/z

Figure 4.15. The isotope distributions of the 1542.004+ and 1570.454+ ions in Figure 4.10.
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Figure 4.16. The product–ion spectrum of the MS3 analysis of the 1313.275+ ion at m/z
1542.00. The peptide sequence of the 1542.004+ ion: PIKYLEFISDAIHVLHSKHPGDFGADA
QGAMTKALELFRNDIAA KYKELGFQG
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Figure 4.17. The product–ion spectrum of the MS3 analysis of the 1313.275+ ion at m/z
1570.45. The peptide sequence of the 1570.454+ ion: IPIKYLEFISDAIIHVLHSKHPGDFGAD
AQGAMTKALELFRNDIAAKYKELGFQG

4.3.3.4. Determination of the Pt(NH3) binding site on His97-Gly153
The binding site of Pt(NH3) on the peptide His97-Gly153 is determined by the
MS3 analyses of the 1313.275+ ion at two Pt-containing fragment ions 972.153+ and
1445.073+ in Figure 4.10.

(I) The MS3 analysis of the 1313.275+ ion at m/z 972.15

Figure 4.18. shows the isotope distribution of the 972.153+ ion and the
product-ion spectrum of the MS3 analysis of the 1313.275+ ion at m/z 972.15. The
isotope distribution of the 972.153+ ion indicates it is a triply charged Pt-containing
fragment ion. According to the mass of the 1313.275+ ion, the 972.153+ ion is the
84

counterpart of the y342+ ion (m/z 1815.91) in Figure 4.10., estimated to be a
Pt-containing b233+ ion according to the structure of the 1313.275+ ion. Several b ions
of the 1313.275+ ion in Figure 4.18., such as b3+, b172+, b182+, and b192+ ions, confirm
the structure of the 972.153+ ion as the b233+ ion. In Figure 4.18, the 1268.732+ ion is
the counterpart of the b3+ ion (m/z 379.27) based on the mass of the 972.153+ ion.
1388.822+ and 1325.452+ ions are produced by losing H and HK residues from the
972.153+ ion respectively, consistent with the peptide sequence of the 972.153+ ion as
His97-His119 starting with HK residues at the N terminus. Importantly, the
appearance of the intense b192+ ion at m/z 1116.55 indicates that Pt is not bound to the
amino acid residues from His98 to Lys116, but bound to the side chains of HSKH
residues. The expected mass of the Pt bound HSKH fragment is 683.35 Da. However,
the 666.09+ ion is observed, arising from neutral loss of either a H2O or a NH3 from
the HSKH residues during the MS3 analysis.
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Figure 4.18. The isotope distribution of the 972.153+ ion and the MS3 analysis of the 1313.275+
ion at m/z 972.15. The peptide sequence of the 972.153+ ion: (His97-His119) HKIPIKYLEFISD
AIIHVLHSKH

(II) The MS3 analysis of the 1313.275+ ion at m/z 1444.45

The 1444.453+ ion is a Pt-containing y ion at the C terminus according to its
isotope distribution and the y ions (y8+, y12+, y272+, y312+ and y342+) of the peptide
His97-Gly153 in the product-ion spectrum of the MS3 analysis of the 1313.275+ ion at
m/z 1444.45, Figure 4.19. In Figure 4.19., 1361.64+ and 971.55+ ions are
complementary to the y272+ (m/z 1486.45) and y312+ (m/z 1681.27) ions, respectively.
The high abundance of the y342+ ion (m/z 1816.55) indicates that Pt is not bound to the
amino acid residues from Pro120 to Gly153. The expected mass of the counterpart of
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the y342+ ion is 700.25 Da, very close to the theoretical mass of the Pt(NH3) compound
bound HSKH residues (theoretical mass 700.23). However, an abundant ion at m/z
684.55 appears in Figure 4.19., the mass of which differs from 700.25 Da by -15.70
Da, suggesting that the 684.55+ ion might be produced by losing the NH3 on the
Pt(NH3) compound. Hence, Pt(NH3) in the 1313.275+ ion is bound to the side chains
of the HSKH residues in the peptide His97-Gly153. HSKH is the common binding
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Figure 4.19. The isotope distribution of the 1444.453+ ion and the MS3 analysis of the
1313.275+ ion at m/z 1444.45 and. The peptide sequence of the 1444.453+ ion: (His116-Gly153)
HSKHPGDFGADAQGAMTK ALELFRNDIAAKYKELGFQG
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4.3.3.5. The assignment of the residues coordinated to Pt(NH3) in the
HSKH residues
The primary adducts of cisplatin and transplatin with Mb are bidentate adducts,
suggesting there are two residues in the HSKH residues coordinated to Pt(NH3)2.
Because Lys118 is protonated at pH 6.8, Pt(NH3)2 binds to two residues among
His116, Ser117, and His119.

The possibility of His116~Ser117 attached to Pt(NH3)2 was examined by reacting
a dipeptide His~Ser with cisplatin and transplatin respectively for 30 h. Both reactions
yielded several adducts. Monoadduct, the Pt(NH3)2(H2O) bound His~Ser, is the
primary adduct, suggesting Pt primarily coordinates to His in the dipeptide His~Ser.
Therefore, Pt(NH3)2 originated from cisplatin and transplatin are not coordinated to
the adjacent amino acid residues His116~Ser117 in Mb. His116 and His119 are the
two possible residues coordinated to Pt(NH3)2 in the Mb-cisplatin and Mb-transplatin
adducts.

The three dimensional (3-D) structure of the polypeptide chain of native Mb is
shown in Figure 4.20. His116, Ser117, and Lys118 are located at the last turn of Helix
G and His 119 is located at the random coil between Helix G and Helix H

12

. As

shown in Figure 4.20., the side chains of His116 and His119 are exposed to the
solvent and close to each other in space, which makes it possible for Pt(NH3)2 connect
these two residues in space to form bidentate adducts. The identification of His116
and His119 as the binding residues is consistent with the detection of the Pt bound
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HSKH fragment ions during the MS3 analyses of the 1313.275+ ion.

Based on the above results, the bidentate Mb-cisplatin and Mb-transplatin
adducts are formed by substituting H2O of the hydrolyzed cisplatin and transplatin
with the side chains of His116 and His119 on Mb. The arrangement of His116 and
His119 on Mb is more suitable to interact with cisplatin than with tranpslatin, leading
to more cooperative interactions between cisplatin and Mb. In addition, the binding
site at His116 and His119 is probably the primary binding site of cisplatin and
transplatin because the 1313.275+ and 1316.685+ ions are the most abundant
Pt-containing fragments observed in the adduct digests.

Helix G

Ser117

His116

Helix H

Lys118
His119

Figure 4.20. The Ribbon diagram of the 3-D structures of the Mb polypeptide chain under
native conditions with the side chains of the HSKH residues displayed 12.
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4.3.4. The stability of the Mb-cisplatin and the Mb-transplatin
adducts
GMP is a good nucleophile for cisplatin and transplatin because it has several
nitrogens in its structure. In order to examine the stability of the Mb-cisplatin and
Mb-transplatin adducts, GMP is mixed with the Mb-cisplatin and Mb-transplatin
adducts at (GMP:the total Mb) molar ratio of 5:1 to compete Pt(NH3)2 on the Mb
adducts as a nucleophile. The monoadduct-GMP adducts [(1:1 Mb-cisplatin)-GMP
and

(1:1

Mb-transplatin)-GMP]

and

the

diadduct-GMP

adducts

[(1:2

Mb-cisplatin)-GMP and (1:2 Mb-transplatin)-GMP] are observed in both the
Mb-cisplatin and Mb-transplatin solutions. Figure 4.21a. and Figure 4.21b. show the
percentages of each Mb species in both solutions at different time over 3 days. The
percentage of each species in both solutions changes similarly. A slight change occurs
for free Mb, but the Mb monoadducts (1:1 Mb-cisplatin and 1:1Mb-transplatin) and
the Mb diadducts (1:2 Mb-cisplatin and 1:2 Mb-transplatin) decrease sharply in half
a day and then remains constant, corresponding to the rapid formation of the
monoadduct-GMP adducts and the diadduct-GMP adducts. Despite the binding of
GMP to the Mb adducts, no Pt compounds are released from Mb according to the
slight change of the percentage of free Mb, which indicates the stability of the
Mb-cisplatin and Mb-transplatin adducts.
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Figure 4.21. The percentage of each Mb species after reacting the Mb adducts with 5’-GMP
for different hours over 3 days: (a) The reaction of Mb-cisplatin adducts with 5’-GMP; (b) The
reaction of Mb-transplatin adducts with 5’-GMP
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4.4. Conclusions
Similar results are obtained in the comparison of the Mb-cisplatin and
Mb-transplatin interactions. The bidentate monoadducts and diadducts are the primary
adducts, yielded by coordinating Pt(NH3)2 to Mb over 30 hours’ interactions.
However, the formation of the Mb-cisplatin adducts is faster and more cooperative
than the formation of the Mb-transplatin adducts. In the determination of the binding
sites, two fragment ions, the 1313.275+ and 1316.685+ ions corresponding to Pt(NH3)
and Pt(NH3)2 bound His97-Gly153 respectively, are observed in both the Mb-cisplatin
and Mb-transplatin adduct digests. The MS3 analyses of the 1313.275+ and 1316.685+
ions indicate that cisplatin and transplatin have a common binding site and are
attached to two residues of HSKH in the peptide His97-Gly153. The interactions of
cisplatin and transplatin with the dipeptide His~Ser and the 3-D structure of native
Mb suggest cisplatin and transplatin are coordinated to His116 and His119 on Mb.
Both the Mb-cisplatin and Mb-transplatin adducts were proved to be stable because
little changes occurred in the percentage of free Mb during the reactions between
GMP with the Mb-cisplatin and Mb-transplatin adducts respectively over three days.
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Chapter 5. A Mass Spectrometric Comparison of the
Binding Sites of Cisplatin on Native and Denatured Ub:
Evidence of the Effect of Protein Conformation on Protein
Platination

5.1. Introduction
Blood plasma protein-cisplatin interactions play important roles in drug efficacy
of cisplatin as an antitumor drug because the blood plasma protein-cisplatin adducts
might serve as a Pt reservoir for DNA platination. However, some of the blood plasma
protein-cisplatin interactions are irreversible, leading to the accumulation of cisplatin
inside tissues and inducing side effects 1. Because of the therapeutic effects of the
blood plasma protein-cisplatin interactions on the cisplatin efficacy, there has been an
increasing interest in determining the binding sites of cisplatin on model proteins in
order to provide insight into their interactions.

Mass spectrometry (MS) based bottom-up and top-down approaches are useful
tools for determination of protein modification sites 2. The bottom-up approach is
conducted

by

proteolytic

digestion

of the
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proteins,

followed

by

liquid

chromatograpy-tandem mass spectrometry (LC-MS/MS) of the obtained digests. The
top-down approach involves direct fragmentation of the proteins in gas phase without
the protein digestion. The obtained fragments are analyzed by high–resolution mass
spectrometry for accurate mass measurement. Because peptides are more suitable for
fragmentation in gas phase than the intact proteins, the bottom-up approach is more
often used for determination of the cisplatin binding sites on the proteins. Dyson et al.
firstly employed the bottom-up approach to determine the binding site of cisplatin on
transferrin

3,4

. Later, the binding sites of carboplatin

5

and Pt(II) iminoethers

6

on

cytochrome c (cyt c) were determined. However, the application of the bottom-up
approach in determination of the binding sites of cisplatin on ubiqutin was
unsuccessful (Ub) 7. Recently, the top-down approach revealed that Met1 was the
primary binding site of cisplatin on Ub 8, which was consistent with the results
suggested by Ub modification 7,9,10.

More recently, our group introduced a strategy to directly determine the primary
binding site of cisplatin on cyt c by coupling Fourier transform mass spectrometry
(FT-MS) with tandem mass spectrometry (MS/MS and MS3)

11

. The high-resolving

power of FT-MS enabled direct analyses of the digests of free cyt c and cyt c adduct
without the LC purification step. The unique fragments in the adduct digest were
characterized by MS/MS and MS3. The primary binding site of cisplatin on cyt c was
determined through interpretation of the product-ion spectra. The proposed method
was successfully applied to determine the primary binding sites of cisplatin on
myoglobin (Mb) 12.
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Although both cyt c and Mb contain Met and His residues, the primary binding
sites of cisplatin on these two proteins are quite different. Cisplatin is primarily bound
to the Met65 residue in cyt c, but His116 and His119 residues are assigned as the
primary residues on Mb attached to cisplatin. Because Met65 in cyt c is exposed to
the solvent and the Met residues in native Mb are located in the hydrophobic core, the
two completely different results suggest that the cisplatin binding sites on a protein
are affected by the protein conformation and cisplatin prefers to bind to the residues
on the surface of the protein13.

Because of the influence of the protein conformation on the cisplatin binding
sites and the fact that Met1 is partially folded inside the Ub polypeptide chain,
cisplatin is expected to bind to residues located at the surface of native Ub other than
Met1. Consistent with this expectation, the interactions of Pt compounds with Ub
yielded several monoadducts under native conditions 7-10,14,15. However, only the Met1
residue was identified as the cisplatin binding site on Ub under physiological
conditions 8.

This paper presents a complete study of the cisplatin binding sites on native Ub
and denatured Ub based on the method reported before 11. Comparison of the binding
sites of cisplatin on native Ub and fully denatured Ub provides evidence regarding the
dependence of the cisplatin binding sites on the conformation of the protein.
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5.2. Experimental
5.2.1. Materials
Ubiquitin (bovine erythrocytes), cisplatin, and ammonium bicarbonate were
purchased from Sigma (St. Louis, MO). Sequencing-grade modified trypsin and all
other chemicals were obtained from Fisher Scientific (Pittsburgh, PA). The Ub
sequence is shown in Figure 5.1.

1 MQIFVKTLTG KTITLEVEPS DTIENVKAKI 30
31 QDKEGIPPDQ QRLIFAGKQL EDGRTLSDYN 60
76
61 IQKESTLHLV LRLRGG

Figure 5.1. The Ub sequence

5.2.2. Formation of native and denatured Ub-cisplatin adducts
Native and denatured Ub-cisplatin adducts were prepared by reacting 100 μM Ub
with cisplatin at 1:10 Ub:cisplaitn molar ratio under native and denatured conditions,
respectively. Water and a 50% MeOH-1% HAc aqueous solution

16

were used as the

solvents under native and denatured conditions, respectively. The formation of the
adducts was examined over 30 h by ESI-MS. Prior to ESI-MS analyses, the native and
denatured Ub solutions were diluted to 300 nM by a 30% MeOH-0.3%HAc solution.
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5.2.3. Trypsin digestion of the Ub-cisplatin adducts
The native and denatured Ub-cisplatin adducts, prepared by incubating the
mixtures of Ub and cisplatin under native and denatured conditions for 27 h, were
digested by trypsin under the same conditions as free Ub. All the Ub solutions were
denatured by a 4-fold volume of a 70% MeOH-25mM NH4HCO3 solution for 10 min.
Subsequently, free Ub and the Ub adducts were digested by trypsin at a protein to
protease ratio of 50:1 (w/w) at 37℃. The digestion proceeded for 75 min and the
obtained digests were diluted with the same volume of the 50%MeOH-0.3%HAc
solution for FT-MS analysis.

5.2.4. ESI-MS and FT-MS analyses
A quadrupole ion trap mass spectrometer (Finnigan LCQTM, San Jose, CA) was
used to examine the formation of the Ub adducts. The digests of free Ub and the Ub
adducts were analyzed on a hybrid linear ion trap Fourier transform (FT) mass
spectrometer (Thermo Finnigan LTQ-FTTM,, San Jose, CA). The same operating
conditions were employed for electrospray the ion source on both of the mass
spectrometers. The spray voltage was set to 4 kV. The heated metal capillary was
maintained at 200℃. The solutions were introduced by direct infusion at a flow rate
of 3 μL/min.
In ESI-MS analyses of the Ub adducts on LCQ, ion optics were optimized at m/z
1257. The ion injection time was 5 ms. ESI-MS mass spectra of the Ub adducts were
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collected in a mass range of m/z 50-2000. MagTran software

17

was used to

deconvolute the acquired ESI-MS spectra. OriginPro 8 software (OriginLab
Corporation, Northampton, MA) was applied to plot the deconvoluted spectra in the
same coordinate.
The digests of free Ub and the Ub adduct digests were analyzed by FT-MS to
determine mass and charge of each species in the digests. The unique fragments in the
adduct digests with characteristic Pt isotope distributions were further analyzed by
MS/MS and MS3 in the linear ion trap to obtain their structural information. During
MS/MS and MS3, the isolation width was set at 5 m/z and 35% of normalized
collision energy (NCE%) was applied to dissociate ions. All the product-ion spectra
were recorded in a full mass range and the isotope distributions of the product ions
were obtained using zoom scan. ExPASy Proteomics Server was used to search the
Ub sequence and perform theoretical mass calculation for peptides and sequence ions.

5.3. Results and Discussion
5.3.1. Formation of the Ub-cisplatin adducts under the native and
denatured conditions
The Ub-cisplatin adducts were prepared by reacting Ub and cisplatin at a molar
ratio of 1:10 (Ub:cisplatin) under the native and denatured conditions, respectively.
Figure 5.2. displays the percentage changes of the formed monoadducts in the total
Ub of both solutions over 30 h. As shown in Figure 5.2., the reaction under the
denatured solution not only has a faster reaction rate but also produces more adducts
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than those yielded under the native solution. But the percentages of the formed
monoadducts in both the solutions increase similarly over 30 h. In both solutions, the
formed monoadducts increase sharply in 8 h and then gradually increase until 18 h,
after which there is a little change in the percentages of the monoadducts. Therefore,
24 h was used to prepare the Ub-cisplatin adducts under both the native and denatured
conditions.
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Figure 5.2. The percentages of the formed Ub-cisplatin monoadducts under the native and
denatured conditions in 30 hours

Figure 5.3. shows the deconvoluted ESI-MS spectra of the Ub-cisplatin adducts
yielded by the Ub-cisplatin interactions for 12 h and 24 h under the native and
denatured conditions, respectively. Comparison of the deconvoluted ESI-MS spectra
between the native and denatured solutions in Figure 5.3. indicates that more free Ub
is converted into the Ub adducts under the denatured conditions than under the native
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conditions over 24 h. Monoadducts are the only adducts observed under the denatured
conditions. However, a small amount of diadduct is also observed under the native
conditions.

The monoadducts in both solutions are assigned in detail, shown in Figure 5.3.
Under the native conditions, the peaks at 8757.4 Da, 8774.1 Da, 8792.0 Da, 8812.0
Da, and 8828.0 Da, correspond to five monoadducts, (b) Ub-Pt, (c) Ub-Pt(NH3), (d)
Ub-Pt(NH3)2, (e) Ub-Pt(NH3)2(H2O), and (f) Ub-Pt(NH3)2(H2O)2, respectively,
according to their mass shifts from (a) free Ub (8564.0 Da). Under denatured
conditions, only three peaks at 8757.4 Da, 8774.1 Da, and 8833.0 Da are observed
and assigned as the monoadducts (b) Ub-Pt, (c) Ub-Pt(NH3), and (g)
Ub-Pt(NH3)(CH3CO2).

The peaks corresponding to the monoadducts yielded under the native and
denatured conditions in Figure 5.3. exhibit different distribution patterns. Under the
native conditions, the peak arising from the bifunctional adduct Ub-Pt(NH3)2 is the
most intense peak among the five monoadducts and the intensity of the peaks
corresponding to the other four monoadducts is much less intense. However, the peak
corresponding to the trifunctional mononadduct Ub-Pt(NH3) is the most abundant
monoadduct, followed by the peak corresponding to the Ub-Pt adduct under the
denatured conditions.
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Figure 5.3. The deconvoluted ESI mass spectra of the Ub monoadducts yielded by the
Ub-cisplatin interactions under native and denatured conditions over 12 h and 24 h,
respectively. Peak assignment: (a) free Ub; (b) Ub-Pt; (c) Ub-Pt(NH3); (d) Ub-Pt(NH3)2; (e)
Ub-Pt(NH3)2(H2O); (f) Ub-Pt(NH3)2(H2O)2; (g) Ub-Pt(NH3)(CH3CO2).

5.3.2. Determination of the cisplatin binding sites on Ub under the
native and denatured conditions
Ub is a tightly folded protein and unable to be digested under the native
conditions. Therefore, a 4-fold volume of a 70% MeOH-25mM NH4HCO3 solution
was added to the native Ub solution in order to denature Ub before trypsin digestion.
The Ub adducts in the denatured condition were diluted by the same method in order
to increase pH and ionic strength of the solution for trypsin digestion. Afterwards, the
Ub species in both the Ub solutions were digested by trypsin for 75 min. Free Ub was
digested under the same conditions and its digest was used as the control.
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The FT-MS spectra of the digests of free Ub and the Ub adduct digests are
displayed in Figure 5.4., 5.5., and 5.6. The FT-MS spectra of the Ub adduct digests are
quite different from the FT-MS spectrum of the free Ub digest. Most fragments in the
free Ub digest are multiply charged (3+-5+) and observed at over m/z 1000 in Figure
5.4., suggesting the incomplete digestion of free Ub under the experimental conditions.
In contrast, the digestion of the Ub adducts yielded under both the native and
denatured conditions was more complete because most of fragments in the adduct
digests have low charge states (1+ to 3+) and are observed below m/z 1200 in Figure
5.5. and Figure 5.6. The more complete digestion of the adducts than the digestion of
the free Ub suggests that the binding of cisplatin on Ub might promote Ub
denaturation.
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Relative Intensity (%)
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Figure 5.4. The free Ub digest

Relative Intensity (%)

Figure 5.5. The digest of the Ub adduct obtained under the native conditions

Figure 5.6. The digest of the Ub adduct obtained under the denatured conditions
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Because most fragments in the adduct digests have low molecular weight,
platination of a fragment can be indicated by a broader isotope distribution of the
fragment than a peptide of similar size. After careful examination of the isotope
distributions of the fragments in Figure 5.5. and Figure 5.6., the 876.402+, 975.41+,
and 1008.472+ ions in Figure 5.5. and the 975.41+, 1148.923+, and 1631.832+ ions in
Figure 5.6. were identified as the Pt-compound containing fragments according to the
characteristic Pt isotope distributions, displayed in Figure 5.7. and Figure 5.8. All
these ions were subjected to MS/MS and MS3 analyses in order to locate the
platination sites on the corresponding peptides and thereby determine the binding sites
of cisplatin on the native and denatured Ub.

Figure 5.7. The isotope distributions of three Pt-compound containing fragments, the 876.402+,
975.41+, and 1008.472+ ions, in the native Ub adduct digest.
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Figure 5.8. The isotope distributions of three Pt-compound containing fragments, the 975.41+,
1148.923+, and 1631.832+ ions, in the denatured Ub adduct digest

5.3.2.1. Determination of cisplatin binding sites on native Ub
5.3.2.1.1. The binding site of Pt(NH3)2 on the 876.402+ ion
Figure 5.9. shows the product-ion spectrum of the MS/MS analysis of the
876.402+ ion, in which two fragment ions at m/z 678.18 and 977.36 exhibit Pt isotope
distributions. The most abundant 858.822+ ion arises from neutral loss of the parent
ion. Mass difference between the fragment ions assigned as y6+, y8+, y9+, and y10+ in
Figure 5.9. enabled identification of KEGI (L) residues in the 876.402+ ion. Because
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the residues KEGI is only present in the peptide I30-R42 yielded by trypsin digestion
of Ub, the peptide I30-R42 is assigned as the peptide of the 876.402+ ion. The mass of
the peptide I30-R42 (theoretical mass44 1522.77 Da) differs from the mass of the
876.402+ ion by 228.014 Da, suggesting the 876.402+ ion (measured mass 1750.80 Da)
arises from the Pt(NH3)2 bound peptide I30-R42 (theoretical mass 1750.79 Da).

The binding site of Pt(NH3)2 on the peptide I30-R42 was determined by the
MS3 analysis of the 876.402+ ion at m/z 977.36, the result of which is displayed in
Figure 5.10. In Figure 5.9. and Figure 5.10., most of the assigned Pt-containing
sequence ions exhibit the loss of a single proton, suggesting that one proton on the
amino acid residue side chains might be displaced by Pt.

The assigned Pt-containing an, bn, and cn sequence ions in Figure 5.10. confirm
the peptide sequence of the 876.402+ ion. The abundance of the [c3+Pt-H]+ and
[b4+Pt-H]+ ions suggests that Pt is not associated with the amino acid residues from
E34-R42. In Figure 5.9., several abundant y ions (y3+, y6+, y9+, and y10+) also indicate
that the binding site of Pt(NH3)2 is not at the C terminus but at the N terminus of the
peptide I30-R42. Therefore, the MS/MS and MS3 analyses of the 876.402+ ion
indicate that the binding sites of Pt(NH3)2 are in the residues I30-K33. Because I30 is
a nonpolar residue and K33 is protonated in solution, Q31 and D32 are assigned as the
residues associated with Pt(NH3)2 to form the Ub- Pt(NH3)2 bifunctional monoadduct.
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Figure 5.9. The product-ion spectrum of the MS/MS analysis of the 876.402+ ion, overlaid with
the isotope distribution of the 977.36+ product ion. The peptide sequence of the 876.402+ ion:
(I30-R42) IQDKEGIPPDQQR
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Figure 5.10. The product-ion spectrum of the MS3 analysis of the 876.402+ion at m/z 977.36. The
peptide sequence of the 977.36+ ion: (I30-I36) IQDKEGI
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5.3.2.1.2. The binding sites of Pt(NH3) on the 975.41+ ion
The product-ion spectrum of MS/MS analysis of the 975.41+ ion is displayed in
Figure 5.11. Most of the product ions in Figure 5.11. are associated with Pt according
to their isotope distributions. The base peak at m/z 958.27 arises from neutral loss of
one NH3 from the 975.41+ ion. The 812.18+ ion is produced by the loss of the K
residue (theoretical mass 146.11 Da) at the C terminus from the 958.27+ ion according
to the mass difference (146.09 Da) between the 958.27+ and 812.18+ ions. The mass
difference between the 713.09+ and 958.27+ ions is 245.18 Da, indicating that the
713.09+ ion arises from the loss of the VK residues (theoretical mass 245.17 Da) from
the 958.27+ ion at the C terminus. The VK residues are observed in the peptides
M1-K6 (theoretical mass 764.42 Da) and the mass of the 975.41+ ion exactly matches
the mass of one Pt(NH3) bound peptide M1-K6 (theoretical mass 975.41Da), which
indicates that the 975.41+ ion arises from the Pt(NH3) bound the peptide M1-K6. The
Pt-compound containing b ions and y3+ ion in Figure 5.11. confirm the identification
of the 975.41+ ion.

The high intensity of the 713.09+ ion indicates that the peptide bond F4~V5 is
ready to fragment, suggesting Pt is associated to the M1-F4 residues. The low
intensity of Pt bound b2+ and b3+ ions suggests the tight association of Pt with the
M1-F4 residues stabilized the peptide bonds Q2~I3 and I3~F4. According to the
structures of the peptide residues M1-K6 and Pt chemistry, the Pt(NH3) moiety may
interact with S in the M1 residue, N in the amino group at the N terminus, and N in
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the Q2 residue, leading to the formation of the trifunctional Ub-Pt(NH3) adduct in the
solution.
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Figure 5.11. The product-ion spectrum of the MS/MS analysis of the 975.41+ ion. The peptide
sequence of the 975.41+ ion: (M1-K6) MQIFVK

5.3.2.1.3. The Pt(NH3)2 binding sites on the 1008.472+ ion
Figure 5.12. shows the product-ion spectrum of the MS/MS analysis of the
1008.472+ ion. The mass difference of the assigned y3+, y4+, y5+, y6+, y11+, y12+, y13+,
and y14+ sequence ions in Figure 5.12. indicates that the peptide sequence of the
1008.472+ ion is T12-K27. According to the mass difference (228.01 Da) between the
1008.472+ ion and the peptide T12-K27 (theoretical mass 1786.93 Da), Pt(NH3)2
(theoretical mass 228.03 Da) is assigned as the Pt moiety in the 1008.472+ ion.

The abundant y ions in Figure 5.12. suggest the binding site of the Pt(NH3)2
moiety is at the N terminus. The 622.18+ ion, assigned as the [b4+Pt-H]+ ion, is
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complementary to the abundant y12+ ion at m/z 1359.64 because the mass sum of these
two ions is 1981.82 Da, which is 35.12 Da less than the mass of the 1008.472+ ion,
arising from neutral loss of the parent ion during the MS/MS analysis. The MS3
analysis of the 1008.472+ ion at m/z 622.18 indicates that the 622.18+ ion is very
stable in gas phase and unable to fragment in MS3 analysis to provide detailed
structural information. Because the Pt(NH3)2 moiety binds to two residues to form
bifunctional adducts and both I and L in the TITL residues in the 622.18+ ion are
nonpolar residues, T12 and T14 residues in the 1008.472+ ion are determined as the
residues associated with the Pt(NH3)2 moiety.

To sum up, three cisplatin binding sites were identified by MS/MS and MS3
analyses of the 876.402+, 975.41+, and 1008.472+ ions in the native Ub adduct digest.
Among these three fragments, the peak corresponding to the 1008.472+ ion is the most
intense and the peak corresponding to the 876.402+ ion is the least intense in the
FT-MS spectrum, suggesting T12 and T14 residues are the most possible binding sites,
followed by M1 and some residues at the N terminus, and Q31~D32 residues .
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Figure 5.12. The product-ion spectrum of MS/MS analysis of the 1008.472+ ion, overlaid with
the isotope distribution with the product ion 622.18+. The sequence of the 1008.472+ ion:
(T12-K27) TITLEVEPSDTIENVK

5.3.2.2. Determination of the cisplatin binding site on denatured Ub
The 975.41+, 1148.923+, and 1623.322+ ions arising from three Pt-containing
fragments are observed in the FT-MS spectra of the denatured Ub adduct digest,
Figure 5.6. The peak corresponding to the 975.41+ ion, identified as the Pt(NH3)
bound M1-K6 by Figure 5.9., is the most abundant and its intensity covers over 80%
of the peak intensity of all the three peaks corresponding to the Pt-containg fragments
in Figure 5.6.
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Figure 5.13. and Figure 5.14. show the MS/MS analyses of the 1148.923+ and
1623.322+ ions, respectively. The 713.09+ fragment ion corresponding to the
[b4+Pt-H]+ ion in Figure 5.9. was also observed in both Figure 5.13. and Figure 5.14.,
indicating that the 1148.923+ and 1623.322+ ions are the same as the 975.41+ ion that
arises from the binding of Pt(NH3) to three residues at the N-terminal of Ub.
According to Figure 5.13. and Figure 5.14., the 1148.923+ and 1623.322+ ions are
assigned as the Pt(NH3) bound peptide M1-K29 and the Pt(NH3) bound peptide
M1-K27. The result indicates that M1 is the specific cisplatin binding site under the
denatured conditions. Pt(NH3) binds to the S atom of M1, the N atom of the amino
group at the N terminus, and the N atom of the side chain of Q2 under denatured
conditions.
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Figure 5.13. The product-ion spectrum of the MS/MS analysis of the 1148.923+ ion. The
peptide sequence of the 1148.923+ ion: M1-K29 MQIFVKTLTGKTITLEVEPSDTIENVKAK
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Figure 5.14. The product-ion spectrum of the MS/MS analysis of the 1623.322+ ion. The peptide
sequence of the 1623.322+ ion: M1-K27 MQIFVKTLTGKTITLEVEPSDTIENVK

In short, three different binding sites of cisplatin on Ub are observed under the
native conditions, but only one cisplatin binding site is determined for the denatured
Ub. Under native conditions, the residues T11 and T13 located on the surface of the
Ub polypeptide chain are identified as the primary binding sites due to the steric
effects. But M1 at N-terminus is the single binding site of cisplatin on Ub under
denatured conditions.
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5.4. Conclusions
Although the Ub-cisplatin interactions are more complete under denatured
conditions than under native conditions, the variety of monoadducts obtained under
denatured conditions is less than that obtained under native conditions. Five types of
monoadducts were observed under native conditions and three types of monoadducts
were observed under denatured conditions. Consistent with this result, more cisplatin
binding sites are identified on native Ub than denatured Ub. Under native conditions,
Ub has three binding sites T12 and T14, M1, and Q31 and D32, but M1 is the only
binding site determined for denatured Ub.

The comparison of the binding sites of cisplatin on native and denatured Ub
indicates that cisplatin has high affinity to M1 without steric hindrance. However, for
a tightly folded protein, cisplatin will interact with the nucleophiles at surface, even
the oxygen containing side chains to form bifunctional adducts instead of overcoming
the steric effects to bind to the M1 residue partly buried in the interior of the protein
structure. As a result, the conformation of a protein has a strong effect on the cisplatin
binding sites. This rule is important in our understanding of interactions between
cisplatin and blood plasma proteins in biological fluids.

115

5.5. References

(1) Reedijk, J. Chem. Rev. 1999, 99, 2499-2510.
(2) Wehr, T. LCGC North America. 2006, 24, 1004-1010.
(3) Khalaila, I.; Allardyce, C. S.; Verma, C. S.; Dyson, P. J. ChemBioChem. 2005, 6,
1788-1795.
(4) Allardyce, C. S.; Dyson, P. J.; Coffey, J.; Johnson, N. Rapid Commun. Mass
Spectrom. 2002, 16, 933-935.
(5) Yang, G.; Miao, R.; Jin, C.; Mei, Y.; Tang, H.; Hong, J.; Guo, Z.; Zhu, L. J. Mass
Spectrom. 2005, 40, 1005-1016.
(6) Casini, A.; Gabbiani, C.; Mastrobuoni, G.; Pellicani, R. Z.; Intini, F. P.; Arnesano,
F.; Natile, G.; Moneti, G.; Francese, S.; Messori, L. Biochemistry. 2007, 46,
12220-12230.
(7) Gibson, D.; Costello, C. E. Eur. Mass Spectrom. 1999, 5, 501-510.
(8) Hartinger, C. G.; Tsybin, Y. O.; Fuchser, J.; Dyson, P. J. Inorg. Chem. 2008, 47,
17-19.
(9) Peleg-Shulman, T.; Gibson, D. JACS. 2001, 123, 3171-3172.
(10) Peleg-Shulman, T.; Najajreh, Y.; Gibson, D. J. Inorg. Biochem. 2002, 91,
306-311.
(11) Zhao, T.; King, F. L. J. Am. Soc. Mass Spectrom. 2009, 20, 1141-1147.
(12) Zhao, T.; King, F. L. Submitted to J. Inorg. Biochem.
(13) Cox, M.C.; Barnham, K.J.; Frenkiel, T.A.; Hoeschele, J.D.; Mason, A.B.; He, Q.Y.;
Woodworth, R.C.; Sadler, P. J. J. Bio. Inorg. Chem. 1999, 4, 621-631.
(14) Najajreh, Y.; Ardeli-Tzaraf, Y.; Kasparkova, J.; Heringova, P.; Prilutski, D.;
Balter, L.; Jawbry, S.; Khazanov, E.; Perez, J. M.; Barenholz, Y.; Brabec, V.;
Gibson, D. J. Med. Chem. 2006, 49, 4674-4683.
(15) Hartinger, C. G.; Ang, W. H.; Casini, A.; Messori, L.; Keppler, B. K.; Dyson,
P. J. J. Anal. Atom. Spectrom. 2007, 22, 960-967.
(16) Kodali Ravindra Babu, A. M., Douglas, D. J. J. Am. Soc. Mass Spectrom.
2001, 12, 317-328.
(17) Zhang, Z.; Marshall, A. G. J. Am. Soc. Mass Spectrom. 1998, 9, 225-233.

116

Future Directions

In this dissertation, a mass spectrometric method was developed for
determination of the primary binding site of cisplatin on various proteins by coupling
Fourier transform mass spectrometry (FT-MS) with tandem mass spectrometry
(MS/MS and MS3). This approach was successfully applied to determine the primary
binding sites of cisplatin on cytochrome c (cyt c), cisplatin and transplatin on Mb and
the major binding sites of cisplatin on ubiquitin (Ub). These results suggest the
developed approach can be potentially applied to determine the major binding sites of
Pt metallodrugs on a wide variety of proteins. Because a large protein will result in a
more complex adduct digest, liquid chromatography (LC) may be necessary before
FT-MS analysis of the adduct digest for larger proteins such as the most abundant
protein in the blood plasma, human serum albumin (HSA).

The interactions of cisplatin and transplatin with Mb were also compared in
binding kinetics, the formed adducts, and their primary binding sites on Mb. The
results indicate that cisplatin and transplatin have similar interactions with Mb.
Because Mb has a tight globular structure, similar to HSA, this result might suggest
that the completely different anticancer activity between cisplatin and transplatin are
not caused by the different interactions of cisplatin and transplatin with the blood
plasma proteins. The above conclusion may be tested by comparing the interactions of
cisplatin and transplatin with HSA using the similar mass spectrometric approaches
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employed in this dissertation.

Finally, the obtained results in determination of cisplatin binding sites on model
proteins indicate that the binding sites of cisplatin on proteins are influenced by the
conformation of the proteins. Cisplatin is primarily attached to the Met65 residue in
cyt c, but His116 and His119 residues are the residues that are bound to cisplatin on
Mb because of the tight folding of Mb. The conformation effect on the binding sites of
cisplatin on a protein was tested by comparing the binding sites of cisplatin on native
and denatured Ub. Three binding sites are observed for native ubiquitin because of the
partial folding of Met1 inside native Ub. Met1 is the specific binding site of cisplatin
on fully denatured Ub. Therefore, the results suggest the protein conformation needs
to be considered during prediction of the binding sites of Pt metallodrugs on proteins.

In conclusion, the developed mass spectrometric methods and the results can
provide insights into the interactions of Pt metallodrugs with blood plasma proteins.
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